[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 159
1. Zeng X, Wu SF, Zhou WX, Li DJ, Gao J, Liang ZY, Liu TH: [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Jul;35(7):398-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer].
  • OBJECTIVE: To explore epidermal growth factor receptor (EGFR) and HER2 gene status, to assess the correlation between EGFR and HER2 gene status, and to investigate the role of copy number increase and amplification of EGFR gene and HER2 gene in the tumorigenesis and disease progression of non-small-cell lung cancer.
  • METHODS: Using Path Vysion kit and LSI EGFR SpectrumOrange/CEP7 Spectrum Green probes, EGFR gene and HER2 gene status were evaluated by fluorescence insitu hybridization (FISH) using formalin-fixed, paraffin-embedded samples from 31 patients with non-small-cell lung cancer, including 20 adenocarcinomas, 2 squamous cell carcinomas, 2 large cell carcinoma, 4 bronchoalveolar carcinomas and 3 adenosquamous carcinomas.
  • Of 25 cases without EGFR gene non-amplification, four tetrasomy and 5 polysomy were detected.
  • CONCLUSIONS: EGFR or HER2 copy number increase is much more frequent than gene amplification in no-small-cell lung cancer.
  • Both genes are involved in the tumorigenesis and development of lung cancer.
  • EGFR/HER2 dimer is one of the predominant heterodimerization types in lung cancer.
  • The interactions between EGFR and HER2 may play a rule in the progression of non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Genes, erbB-1 / genetics. Genes, erbB-2 / genetics. Lung Neoplasms / pathology


2. Katz SL, Das P, Ngan BY, Manson D, Pappo AS, Sweezey NB, Solomon MP: Remote intrapulmonary spread of recurrent respiratory papillomatosis with malignant transformation. Pediatr Pulmonol; 2005 Feb;39(2):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extension into lung parenchyma occurs in less than 1% of patients and has a low risk of malignant transformation.
  • We describe a case of recurrent respiratory papillomatosis with extensive parenchymal involvement and adenosquamous carcinoma in a 14-year-old girl.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cell Transformation, Neoplastic. Laryngeal Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Papilloma / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15532092.001).
  • [ISSN] 8755-6863
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Kothari RK, Ghosh A, Bhattacharyya SK, Ghosh SK: Adenosquamous carcinoma of oral cavity: a case report. J Indian Med Assoc; 2007 Sep;105(9):531-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of oral cavity: a case report.
  • Histopathological examination of the biopsied material showed features suggestive of adenosquamous carcinoma, but CT-guided fine needle aspiration cytology from lung mass showed evidence of non-keratinising squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Mouth Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338480.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H: Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res; 2008 Oct 15;14(20):6618-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: EML4-ALK is a fusion-type protein tyrosine kinase that is generated by inv(2)(p21p23) in the genome of non-small cell lung cancer (NSCLC).
  • EXPERIMENTAL DESIGN: Primers were designed to detect all possible in-frame fusions of EML4 to exon 20 of ALK, and a single-tube multiplex RT-PCR assay was done with total RNA from 656 solid tumors of the lung (n = 364) and 10 other organs.
  • RESULTS: From consecutive lung adenocarcinoma cases (n = 253), we identified 11 specimens (4.35%) positive for fusion transcripts, 9 of which were positive for the previously identified variants 1, 2, and 3.
  • No fusion transcripts were detected for other types of lung cancer (n = 111) or for tumors from 10 other organs (n = 292).
  • CONCLUSIONS: These data reinforce the importance of accurate diagnosis of EML4-ALK-positive tumors for the optimization of treatment strategies.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Exons / genetics. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / genetics. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Cell Transformation, Neoplastic. Chromosome Inversion. DNA Primers / chemistry. Gene Rearrangement. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18927303.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm
  •  go-up   go-down


5. Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, Masuda N, Eguchi K, Mitsudomi T, Yokota S, Segawa Y, Ichinose Y, Fukuoka M, Saijo N: Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res; 2010 Feb;30(2):557-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
  • The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Humans. Japan. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome. Young Adult


6. Yu JQ, Yang ZG, Austin JH, Guo YK, Zhang SF: Adenosquamous carcinoma of the lung: CT-pathological correlation. Clin Radiol; 2005 Mar;60(3):364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the lung: CT-pathological correlation.
  • AIM: To correlate CT morphological features and histopathological findings of adenosquamous carcinoma of the lung.
  • MATERIALS AND METHODS: In all, 29 patients underwent contrast-enhanced CT of an adenosquamous carcinoma of the lung, followed by resection of the cancer.
  • These CT features corresponded mainly to solid tumour growth, which was composed of both squamous cell carcinomatous and adenocarcinomatous tissue.
  • CONCLUSION: Adenosquamous carcinoma of the lung is shown to be characteristically a solid, lobulated nodule or mass, more commonly peripheral than central.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710140.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Hu YY, Sun XR, Lin XP, Liang PY, Zhang X, Fan W: [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up]. Ai Zheng; 2009 Sep;28(9):994-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up].
  • BACKGROUND AND OBJECTIVE: Accurate and early diagnosis of recurrence for cervical cancer after the treatment and aggressive salvage treatment could improve the prognosis of this disease.
  • Serum squamous cell carcinoma antigen (SCCAg) is the most commonly used tumor marker for the detection of asymptomatic recurrence of cervical cancer.
  • This study was to evaluate the application and value of (18)F-FDG PET/CT in cervical cancer with elevated of serum SCCAg level during the follow-up.
  • METHODS: Thirty-one patients with cervical cancer with elevated serum SCCAg level during the follow-up undergoing (18)F-FDG PET/CT in Sun Yat-sen University Cancer Center between August 2005 and November 2008 were entered into this retrospective study.
  • RESULTS: All 31 patients'pathological examination showed squamous cell carcinoma, including three adenosquamous carcinoma.
  • Of these 31 patients, three were confirmed to have local recurrent disease, 27 were verified to have metastatic disease and one was diagnosed as primary lung squamous cell carcinoma by pathological or clinical manifestations.
  • The total detection rate of PET/CT for malignancy was 100% (31/31); the diagnostic accuracy of PET/CT for recurrent cervical cancer was 96.8% (30/31).
  • CONCLUSIONS: An elevated level of SCCAg in cervical cancer during the follow-up indicates tumor recurrence.
  • [MeSH-major] Antigens, Neoplasm / blood. Carcinoma, Squamous Cell / radiography. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Serpins / blood. Uterine Cervical Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Carcinoma, Adenosquamous / blood. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Radiopharmaceuticals. Retrospective Studies. Tomography, X-Ray Computed


8. Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E: Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol; 2007 Aug;33(6):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in non-small cell lung cancer: a population-based study.
  • BACKGROUND: A retrospective study including all patients with non-small cell lung cancer carcinoma in a population-based registry was performed to characterize gender differences in lung cancer and to analyze the factors influencing prognosis in women.
  • METHODS: We retrieved through the Tuscan Cancer Registry (RTT) archive 2,523 lung tumor cases diagnosed during the period 1996-1998 in the provinces of Florence and Prato, central Italy.
  • We compared the prognosis within 464 non-small lung cancer women and 1,798 men in a population-based case series.
  • The influence of the following variables on postoperative survival were analyzed: age, cell type, pathologic T and N status, site of tumor and type of surgical resection.
  • RESULTS: The age at diagnosis was similar in women and in men.
  • Women were significantly more likely to have adenocarcinoma but less likely to have squamous cell carcinoma compared with men.
  • CONCLUSIONS: Lung cancer was more frequent in men than in women, but overall survival is similar.
  • Differences in lung cancer histology and rate of pneumonectomies were found between men and women.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / epidemiology. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Age Factors. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Follow-Up Studies. Humans. Italy / epidemiology. Lymph Node Excision / statistics & numerical data. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / statistics & numerical data. Population Surveillance. Prognosis. Registries. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306497.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Achcar Rde O, Nikiforova MN, Dacic S, Nicholson AG, Yousem SA: Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol; 2009 Jun;40(6):854-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma.
  • The translocation t(11;19)(q21;p13) results in the gene fusion of mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 genes that is the major chromosomal abnormality observed in mucoepidermoid carcinomas of salivary glands but has not been studied in bronchopulmonary mucoepidermoid carcinoma.
  • To investigate the importance of the mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion gene in bronchopulmonary mucoepidermoid carcinoma tumorigenesis and its differential diagnosis with primary pulmonary non-small-cell carcinomas, we evaluated the presence of the mammalian mastermind like 2 gene rearrangement and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion in formalin-fixed, paraffin-embedded tissue sections from 17 adult bronchopulmonary mucoepidermoid carcinoma, 16 adenosquamous carcinomas, 24 squamous cell carcinomas, and 41 primary adenocarcinomas by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction.
  • We detected mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization analysis in 13 (77%) of 17 bronchopulmonary mucoepidermoid carcinoma cases (10 of 10 being low grade and 3 of 7 being high grade).
  • Reverse transcriptase polymerase chain reaction analysis confirmed positive fluorescence in situ hybridization results in 6 (43%) of 14 mucoepidermoid carcinoma cases.
  • None of the squamous, adenosquamous, or adenocarcinoma cases revealed the mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization, and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product by reverse transcriptase polymerase chain reaction was not identified specifically in our adenosquamous carcinoma cases.
  • In conclusion, our study demonstrates that mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product can be detected by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction analysis performed on low- and high-grade primary bronchopulmonary mucoepidermoid carcinoma and can be used to help discriminate low- and high-grade mucoepidermoid carcinoma from adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma mimics in histologically challenging cases.
  • [MeSH-major] Bronchial Neoplasms / genetics. Carcinoma, Mucoepidermoid / genetics. DNA-Binding Proteins / genetics. Lung Neoplasms / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenosarcoma / genetics. Adenosarcoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Gene Fusion. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269006.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / MECT1-MAML2 fusion protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


10. Zhao ZL, Huang QY, Xu S, Zhang L, Zhao HR: [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof]. Zhonghua Yi Xue Za Zhi; 2006 Dec 19;86(47):3362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof].
  • OBJECTIVE: To investigate the expression of promyelocytic leukaemia (PML) protein in lung carcinomas and the clinical significance thereof.
  • METHODS: A tumor tissue microarray with lung samples from 148 patients with lung carcinoma and 5 patients with pulmonary benign tumor, and 7 patients with other benign diseases resected during operation.
  • RESULTS: Four cases of lung carcinoma were excluded because their available cores were less than 3.
  • The remaining 144 lung carcinoma cases included 45 cases with squamous cell carcinoma, 62 with adenocarcinoma, 23 with small cell lung carcinoma (SCLC), 7 with large cell carcinoma, 5 with pleomorphic carcinoma, 1 with carcinoid, and 1 with adenosquamous carcinoma.
  • Among the 5 cases with benign lung tumors, two cases with pulmonary leiomyomas had strong expression of PML.
  • The rates of PML expression on cell nuclei were 31.4% and 8.7% respectively in the non-small cell lung carcinoma (NSCLC) and SCLC samples (chi(2) = 4.968, P = 0.026).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Small Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313836.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  •  go-up   go-down


11. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Bronchial Neoplasms / classification. Bronchial Neoplasms / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


12. Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M, Okayama Lung Cancer Study Group: A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol; 2010 Jan;5(1):99-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
  • BACKGROUNDS: Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer.
  • Two other patients developed interstitial lung disease (grades 1 and 2).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Mutation / genetics. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898258.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


13. Xu ML, Liu Y, Zhong HH, Wu BQ: [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung].
  • OBJECTIVE: To investigate mutations of epidermal growth factor receptor (EGFR) exon 19 and 21 in non-small cell lung carcinoma and to explore their clinicopathological correlations.
  • METHOD: DNA was extracted from the excised tumor specimens of 66 non-small cell lung carcinoma patients by traditional phenol-chloroform and ethanol precipitation.
  • Mutations were more frequently observed in women (9/34, 26.5%) than in men (2/32, 6.3%), in adenocarcinomas (10/43, 23.3%) than squamous (0/13) and adenosquamous carcinomas (1/10).
  • There was no difference in the mutation rates between smokers and non-smokers.
  • Those with adenocarcinoma with bronchiolo-alveolar carcinoma (BAC) components had higher frequency of EGFR mutation (6/11) than those without non-BAC element (4/32, 12.5%).
  • CONCLUSIONS: The mutations appear to occur in highly selected subgroups of lung cancer patients: adenocarcinomas with BAC components and patients of the female gender.
  • The results may offer practical approach to the rapid identification of lung cancer patients who likely respond to EGFR inhibitor therapy.
  • [MeSH-major] Amino Acid Substitution. Carcinoma, Non-Small-Cell Lung / genetics. Gene Deletion. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons. Female. Humans. Male. Middle Aged. Mutation. Sex Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845757.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


14. Okami J, Higashiyama M, Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry: Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications. J Thorac Oncol; 2009 Oct;4(10):1247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications.
  • INTRODUCTION: This retrospective study was designed to identify the predictors of long-term survival and the risk factors for complications after surgery in patients aged 80 years or older with clinical (c)-stage I non-small cell lung cancer.
  • METHODS: The Japanese Joint Committee of Lung Cancer Registry collated the clinicopathological profiles and outcomes of 13,344 patients who underwent pulmonary resection for primary lung cancer in 1999.
  • The data of 367 patients aged 80 years or older with c-stage I non-small cell lung cancer were analyzed for prognostic factors and risk factors for postoperative complications.
  • CONCLUSIONS: Octogenarian patients with c-stage I lung cancer in this study had a satisfactory long-term outcome and low-mortality rate.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Comorbidity. Female. Humans. Lymph Node Excision. Male. Mediastinum / surgery. Neoplasm Staging. Postoperative Complications. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome


15. Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, Mitsudomi T, Yatabe Y: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res; 2008 Oct 1;14(19):6092-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutations in small cell lung cancer.
  • PURPOSE: The vast majority of epidermal growth factor receptor (EGFR) mutations occur in lung adenocarcinoma, and even rare cases of other subtypes with this mutation, such as adenosquamous cell carcinoma, are associated with adenocarcinoma histology.
  • According to this adenocarcinoma-specific nature of EGFR mutation, analysis of EGFR mutations with small cell lung cancers (SCLC) may provide a clue to its histogenesis.
  • The patients were mainly in the light smoker and histologic combined subtype.
  • Notably, in three tumors of the combined SCLC subtype, both components of adenocarcinoma and SCLC harbored an EGFR mutation, whereas gene amplification was detected only in the adenocarcinoma component.
  • CONCLUSIONS: Although EGFR mutations are rare in SCLC, a combined subtype of SCLC with adenocarcinoma in light smokers may have a chance of harboring EGFR mutations.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, erbB-1. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / physiology. Small Cell Lung Carcinoma / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829487.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


16. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively.
  • The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


17. Pardo J, Martinez-Peñuela AM, Sola JJ, Panizo A, Gúrpide A, Martinez-Peñuela JM, Lozano MD: Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol; 2009 Oct;17(5):383-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell carcinoma of the lung: an endangered species?
  • This study aims to evaluate large cell carcinomas (LCC) of the lung with a panel of immunohistochemical markers in an attempt to identify tumors belonging to other categories.
  • The tumors were 82 (81.3%) classic LCC, 7 (6.9%) neuroendocrine LCC, 6 (5.9%) lymphoepithelioma-like LCC, 3 (2.9%) basaloid LCC, 2 (2%) clear cell LCC, and 1 (1%) LCC with rhabdoid phenotype.
  • Characteristic classic LCC immunophenotype was loss of staining with CK5/6, CK14 positive in most squamous cell carcinoma (SCC), lack of MOC 31 positive in most adenocarcinomas, and positive immunoreactivity to EGFR, PDGFR-alpha and c-kit.
  • 16 (19.5%) of 82 classic LCC correspond to undifferentiated adenosquamous carcinomas, since they displayed conflicting immunostaining for markers of both SCC and adenocarcinomas.
  • The use of 7 immunohistochemical markers, consisting of TTF-1, CK7, CK19, p63, 34betaE12, thrombomodulin, and CD44v6, markedly reduces dramatically to less than 10%, the number of classic LCC by readily identifying cases of poorly differentiated SCCs, adenosquamous carcinoma and adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444077.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


18. Picozzi G, Paci E, Lopez Pegna A, Bartolucci M, Roselli G, De Francisci A, Gabrielli S, Masi A, Villari N, Mascalchi M: Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''. Radiol Med; 2005 Jan-Feb;109(1-2):17-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''.
  • PURPOSE: To report the results of a three-year observational pilot study of lung cancer screening with low dose computed tomography (CT) and to present the study design of a randomised clinical trial named as ''Italung-CT''.
  • Indeterminate nodules were managed according to the recommendations of the Early Lung Cancer Action Project.
  • One (1.6%) prevalent lung cancer (adenosquamous carcinoma) and one (2.2%) incident lung cancer (small cell cancer at the first annual examination) were observed, as well as a pulmonary localisation of Hodgkin's lymphoma (at the second annual test).
  • In addition, one subject underwent lung surgery for a chondromatous hamartoma.
  • [MeSH-major] Lung Neoplasms / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Female. Humans. Lung / radiography. Male. Middle Aged. Pilot Projects. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729183.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


19. Matsuoka H, Okada M, Sakamoto T, Tsubota N: Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. Eur J Cardiothorac Surg; 2005 Sep;28(3):380-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age.
  • OBJECTIVE: Patients 80 years or older often present with potentially resectable cases of non-small cell lung cancer.
  • METHODS: From April 1997 through March 2004, 40 consecutive patients with non-small cell lung cancer who were 80-88 years of age underwent complete resection of their tumors, as confirmed pathologically.
  • The histopathologic diagnosis was adenocarcinoma in 22 patients, squamous cell carcinomas in 11, large cell carcinomas in 4, adenosquamous cell carcinomas in 2, and neuro-endocrine cell carcinoma in 1.
  • Eight patients had non-lethal complications (20%), including five with cardiopulmonary complications (parenchymal air leaks persisting for more than 7 days in two patients, interstitial pneumonia in one, bacterial pneumonia in one, and moderate arrhythmias in one) and three with minor complications (depression or confusion).
  • CONCLUSIONS: Advanced age is not a contraindication to curative resection in patients 80-89 years of age with stage I non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Age Factors. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2005 Dec;28(6):912-3; author reply 913 [16275004.001]
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jan;31(1):141; author reply 141-2 [17126024.001]
  • [CommentIn] Eur J Cardiothorac Surg. 2005 Dec;28(6):911-2; author reply 912 [16242942.001]
  • (PMID = 16054820.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H, Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M: Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol; 2007 Nov 1;25(31):4987-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial.
  • PURPOSE: To investigate the role of prophylactic cranial irradiation (PCI) within a trimodality protocol (chemotherapy, chemoradiotherapy, surgery) for patients with operable stage IIIA non-small-cell lung cancer (NSCLC).
  • One hundred six patients were eligible (arm A: 51, arm B: 55), 90 males and 16 females, 50 with squamous cell, 16 with large cell, five with adenosquamous, and 35 with adenocarcenoma (median age, 57 years; range, 37 to 71 years).
  • [MeSH-major] Brain Neoplasms / prevention & control. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Germany. Humans. Male. Middle Aged. Neoadjuvant Therapy


21. Mano H: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci; 2008 Dec;99(12):2349-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
  • However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.
  • Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-associated protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Neoplasms / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Carcinoma, Adenosquamous / genetics. Cell Transformation, Neoplastic. Chromosomes, Human, Pair 2. Exons. Gene Rearrangement. Humans. Male. Middle Aged. Models, Genetic. Translocation, Genetic

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032370.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 71
  •  go-up   go-down


22. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell; 2009 Jun 2;15(6):539-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LPA receptors and autotaxin (ATX/LysoPLD), the primary enzyme producing LPA, are aberrantly expressed in multiple cancer lineages.
  • However, the role of ATX and LPA receptors in the initiation and progression of breast cancer has not been evaluated.
  • We demonstrate that expression of ATX or each edg family LPA receptor in mammary epithelium of transgenic mice is sufficient to induce a high frequency of late-onset, estrogen receptor (ER)-positive, invasive, and metastatic mammary cancer.
  • Thus, ATX and LPA receptors can contribute to the initiation and progression of breast cancer.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1414-24 [17431120.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1111-23 [17574024.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3207-14 [17545524.001]
  • [Cites] Int J Oncol. 2007 Aug;31(2):441-9 [17611702.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Bioinformatics. 2007 Aug 1;23(15):1986-94 [17599930.001]
  • [Cites] Cell. 2007 Aug 24;130(4):597-600 [17719538.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):27229-38 [17652082.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Mod Pathol. 2001 May;14(5):458-64 [11353057.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] J Cell Biol. 2002 Jul 22;158(2):227-33 [12119361.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29584-92 [12048217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11187-92 [12169667.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1706-11 [12670925.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5738-54 [12897145.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):105-14 [14693816.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1115-40 [15258897.001]
  • [Cites] Bioessays. 2004 Aug;26(8):870-81 [15273989.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Cell. 1989 Oct 6;59(1):45-54 [2551506.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3186-96 [8164674.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] Lipids. 1999 Jan;34(1):17-21 [10188592.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4564-76 [10467401.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R640-6 [15535846.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51075-81 [15466414.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1714-25 [15599396.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6027-32 [15837931.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3781-7 [15867374.001]
  • [Cites] Oncogene. 2005 Jun 16;24(26):4220-31 [15824740.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] Drug Discov Today. 2006 Jun;11(11-12):481-93 [16713899.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(13):5015-22 [16782887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8 [16769891.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(24):9302-14 [17030631.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell Cycle. 2007 Mar 15;6(6):667-71 [17361100.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8494-503 [17875688.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • [Cites] Expert Rev Mol Med. 2007;9(28):1-18 [17935635.001]
  • [Cites] Mol Cancer Res. 2007 Nov;5(11):1201-11 [18025263.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11751-9 [18089805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5248-53 [18367674.001]
  • [Cites] Nat Med. 2008 May;14(5):518-27 [18438415.001]
  • [Cites] J Biol Chem. 2008 Jun 13;283(24):16818-29 [18408217.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Oncogene. 2008 Nov 20;27(54):6806-16 [18762810.001]
  • [Cites] J Biol Chem. 2009 Mar 13;284(11):7385-94 [19139100.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9498-508 [15618220.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 May;292(5):C1927-33 [17496233.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1771(7):883-92 [17531530.001]
  • [CommentIn] Cancer Cell. 2009 Jun 2;15(6):457-9 [19477423.001]
  • [ErratumIn] Cancer Cell. 2009 Aug 4;16(2):172
  • (PMID = 19477432.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE15263
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P01 CA064602; United States / NCI NIH HHS / CA / CA099031; United States / NCI NIH HHS / CA / P30CA016672; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / CA64602; United States / NCI NIH HHS / CA / R01 CA082716; United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / R01 CA094118; United States / NCI NIH HHS / CA / CA82716
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; 0 / Receptors, Estrogen; 0 / Receptors, Lysophosphatidic Acid; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.1 / Phosphodiesterase I; EC 3.1.4.39 / alkylglycerophosphoethanolamine phosphodiesterase; EC 3.6.1.- / Pyrophosphatases
  • [Other-IDs] NLM/ NIHMS621073; NLM/ PMC4157573
  •  go-up   go-down


23. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Fischedik K, Stanzel S, Breuer C, Skobel E, Asadpour B, Schmachtenberg A, Buell U, Eble MJ: Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study. Strahlenther Onkol; 2006 May;182(5):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
  • PURPOSE: To determine the maximum tolerated dose (MTD) of gemcitabine every 2 weeks to a concurrent radiotherapy administered during an aggressive program of sequential and simultaneous radio-/chemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Ten patients with histologically confirmed NSCLC were observed and treated in accordance with a combined radio-/chemotherapy protocol.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Positron-Emission Tomography. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Remission Induction. Respiratory Function Tests. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673059.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


24. Li J, Zhang DC, He J, Liu XY, Mu JW, Zhang LZ: [The rule of lymph node metastasis of adenosquamous carcinoma of the lung]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):524-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The rule of lymph node metastasis of adenosquamous carcinoma of the lung].
  • OBJECTIVE: To investigate the rule of lymph node metastasis of adenosquamous carcinoma of the lung.
  • METHODS: The data of 361 surgically treated patients with adenosquamous carcinoma of the lung from October 1965 to June 2003 were collected and retrospectively reviewed.
  • The skip mediastinal lymph node metastasis but N1 negative most commonly metastasized to station 7, then to station 4 from the tumor in the right lung and 5 from the tumor in the left lung.
  • CONCLUSION: The lung cancer growing in a different location has a different route and skipping metastasis to mediastinal lymph nodes.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950701.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshiishi Y, Goya T, Watanabe T: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer; 2007 Feb 15;109(4):741-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
  • BACKGROUND: Tyrosine kinase domain (TKD) gene mutations of the epidermal growth factor receptor gene (EGFR) have proven to be clinically significant in nonsmall-cell lung cancer (NSCLC), particularly in adenocarcinoma.
  • However, TKD mutations together with deletion mutations in the extracellular domain of EGFR (EGFRvIII) have not been fully investigated in NSCLC except for adenocarcinoma.
  • METHODS: EGFR TKD mutations were investigated using direct sequencing and mutation-specific polymerase chain reaction (PCR), and EGFRvIII mutations were examined using reverse transcriptase-PCR in samples from 42 NSCLC patients and 6 NSCLC cell lines excluding adenocarcinoma.
  • RESULTS: EGFR TKD mutations were detected in 1 of 7 (14%) squamous-cell carcinomas with an adenocarcinoma component and 2 of 4 (50%) adenosquamous carcinomas.
  • In contrast, EGFR TKD mutations were not identified in 24 pure squamous-cell carcinomas without any adenocarcinoma component, 7 large-cell carcinomas, or 6 cell lines.
  • EGFRvIII was detected solely in 1 of 7 large-cell carcinomas (14%), but not in 31 squamous-cell carcinomas, 4 adenosquamous carcinomas, or 6 cell lines.
  • CONCLUSIONS: These results suggest that EGFR TKD mutations are found in NSCLCs with an adenocarcinoma element.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Male. Middle Aged. Neoplasm Staging. Prognosis. Protein Structure, Tertiary. Protein-Tyrosine Kinases / chemistry. Survival Rate

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238183.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


26. Mohr U, Ernst H, Roller M, Pott F: Pulmonary tumor types induced in Wistar rats of the so-called "19-dust study". Exp Toxicol Pathol; 2006 Aug;58(1):13-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of primary lung tumor types histologically diagnosed in 28 groups of Wistar rats of the so-called "19-dust study" are described, the total study having been already presented by Pott and Roller (Carcinogenicity study with nineteen granular dusts in rats.
  • Each exposed group was repeatedly instilled intratracheally with a suspension of one type and dose of 13 non-mining dusts differing in at least one of the following properties: chemical composition, density, specific surface area, and mean particle size.
  • In 579 (58%) lungs of 1002 rats which survived more than 26 weeks after the first instillation of GBP, at least one primary lung tumor type was observed, and in 306 (31%) at least two types.
  • Three benign tumor types were diagnosed in the 579 tumor-bearing rats: bronchiolo-alveolar adenoma in 46%, cystic keratinizing epithelioma in 53%, and non-keratinizing epithelioma in 2.6% of the rats.
  • Two of three malignant tumor types (bronchiolo-alveolar carcinoma and squamous cell carcinoma) occurred in 46% and 31% of the tumor-bearing rats, respectively, and adenosquamous carcinoma was diagnosed in 0.9%.
  • In addition, single or multiple metastases from primary tumors of other sites (mainly carcinoma of the uterus) were diagnosed in 14% of the 1002 lungs.
  • [MeSH-major] Adenoma / chemically induced. Air Pollutants / toxicity. Carcinoma / chemically induced. Dust. Lung Neoplasms / chemically induced
  • [MeSH-minor] Aluminum Oxide / toxicity. Aluminum Silicates / toxicity. Animals. Carbon / toxicity. Carcinoma, Adenosquamous / chemically induced. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / chemically induced. Carcinoma, Squamous Cell / pathology. Female. Intubation, Intratracheal. Particle Size. Rats. Rats, Wistar. Silicon Dioxide / toxicity. Specific Pathogen-Free Organisms. Titanium / toxicity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Aluminum oxide .
  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. CARBON .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Exp Toxicol Pathol. 2007 Aug;58(6):407; author reply 409 [17560773.001]
  • (PMID = 16806863.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Aluminum Silicates; 0 / Dust; 15FIX9V2JP / titanium dioxide; 7440-44-0 / Carbon; 7631-86-9 / Silicon Dioxide; D1JT611TNE / Titanium; LMI26O6933 / Aluminum Oxide
  •  go-up   go-down


27. Lin H, Ma YY, Huang CC, Moh JS, Tsai YM, Changchien CC: Oropharyngeal recurrence after bronchial washing for a lung mass in a patient with cervical cancer. Acta Obstet Gynecol Scand; 2006;85(8):1015-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oropharyngeal recurrence after bronchial washing for a lung mass in a patient with cervical cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / secondary. Lung Neoplasms / secondary. Oropharyngeal Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Bronchoalveolar Lavage. Fatal Outcome. Female. Human papillomavirus 18 / isolation & purification. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / virology


28. Kodama K, Okami J, Maeda J, Tokunaga T, Kanzaki R, Fujiwara A, Higashiyama M: [Complete resection of Pancoast tumor following induction chemoradiotherapy improves survival]. Kyobu Geka; 2010 Jan;63(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively analyzed 23 patients with pT3-4, N0-3 Pancoast tumors who underwent combined chest wall resection including the 1st rib, and discuss the anatomical considerations, assessment of induction therapy, and surgical approaches for these cancers.
  • METHODS: Between 1983 and 2006, 23 patients with Pancoast tumors underwent combined resection of the 1st rib at our institute.
  • There were 10 each of squamous cell carcinoma and adenocarcinoma, 2 large cell carcinoma, and 1 adenosquamous carcinoma.
  • RESULTS: A posterior approach was employed in 14 patients, an anterior approach in 7, and a combined anterior and posterior approach in 2.
  • [MeSH-major] Lung Neoplasms / surgery. Pancoast Syndrome / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077826.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Altaner S, Yoruk Y, Tokatli F, Koçak Z, Tosun B, Guresci S, Kutlu K: The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer. Tumori; 2006 Jul-Aug;92(4):323-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer.
  • AIMS AND BACKGROUND: Thyroid transcription factor (TTF-1) is a tissue-specific transcription factor expressed in the epithelial cells of thyroid and lung.
  • The aim of this study was to evaluate the relationship between the expression of TTF-1 and clinico-pathological parameters in pulmonary adenocarcinoma and adenosquamous carcinoma.
  • Twenty-eight patients were diagnosed with adenocarcinoma and 11 with adenosquamous carcinoma.
  • Tumors were classified into 3 groups: a strongly positive group (++) with double dagger 50% tumor cells positive for TTF-1; a weakly positive group (+) with 1-49% positive tumor cells; and a negative group (-) with less than 1% or no positive tumor cells.
  • [MeSH-major] Lung Neoplasms / chemistry. Lymph Nodes / pathology. Nuclear Proteins / analysis. Transcription Factors / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Thyroid Nuclear Factor 1

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036524.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NKX2-1 protein, human; 0 / Nuclear Proteins; 0 / Thyroid Nuclear Factor 1; 0 / Transcription Factors
  •  go-up   go-down


30. Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J, Cheng S: Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion; 2007 Sep;7(5):347-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer.
  • However, roles of mutations and polymorphisms in some diseases are among heated debate, especially for cancer.
  • To investigate the possible role of mtDNA mutations in lung cancer, we sequenced complete mtDNA of lung cancer tissues, corresponding normal (i.e., non-cancerous) lung tissues, and peripheral blood samples from 55 lung cancer patients and examined the relationship between mtDNA mutations or polymorphisms and clinical parameters.
  • There was no association of incidence of specific mtDNA mutation or polymorphism with patients' gender, age at diagnosis, smoking history, tumor type or tumor stage (P>0.05).
  • This study revealed a variety of mtDNA mutations and mtDNA polymorphisms in human lung cancer, some of which might be involved in human lung carcinogenesis.
  • [MeSH-major] DNA, Mitochondrial / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Carcinoma, Adenosquamous / genetics. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. Female. Humans. Male. Middle Aged. Point Mutation

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707697.001).
  • [ISSN] 1567-7249
  • [Journal-full-title] Mitochondrion
  • [ISO-abbreviation] Mitochondrion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


31. Joshita S, Nakazawa K, Sugiyama Y, Kamijo A, Matsubayashi K, Miyabayashi H, Furuta K, Kitano K, Kawa S: Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med; 2009;48(9):687-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course.
  • Herein, we encountered an 89-year-old woman with pancreatic cancer who presented with fever without infective focus, leukocytosis of 45,860 /microL, and elevation of serum granulocyte-colony stimulating factor (G-CSF).
  • Specimens taken at necropsy revealed an adenosquamous carcinoma positive for G-CSF by immunohistochemistry; it was only the second reported case to date.
  • She was finally diagnosed with G-CSF-producing pancreatic cancer.
  • In light of the above, clinicians should consider the presence of G-CSF-producing tumors, including pancreatic cancer, when presented with patients showing leukocytosis of unknown origin and fever without infective focus.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Granulocyte Colony-Stimulating Factor / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Leukocytosis / diagnosis. Leukocytosis / immunology. Lung Neoplasms / immunology. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420814.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 27
  •  go-up   go-down


32. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry: A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol; 2008 Jan;3(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers.
  • PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer.
  • METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry.
  • The data of 13,010 patients with only lung carcinoma histology (97.6%) were analyzed in terms of prognosis and clinicopathologic characteristics.
  • For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8% (n = 161) and 58.3% (n = 127) for IA, 58.0% (n = 77) and 60.2% (n = 79) for IB, 47.1% (n = 17) and 40.6% (n = 29) for IIA, 25.3% (n = 38) and 41.1% (n = 29) for IIB, 29.0% (n = 61) and 28.3% (n = 60) for IIIA, 36.3% (n = 19) and 34.6% (n = 40) for IIIB, and 27.8% (n = 12) and 30.8% for IV (n = 13).
  • For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3% (n = 5642) and 83.9% (n = 4772) for IA, 59.8% (n = 3081) and 66.3% (n = 2629) for IB, 54.1% (n = 205) and 61.0% (n = 361) for IIA, 43.9% (n = 1227) and 47.4% (n = 1330) for IIB, 38.3% (n = 1628) and 32.8% (n = 1862) for IIIA, 32.6% (n = 526) and 29.6% (n = 1108) for IIIB, and 26.5% (n = 198) and 23.1% (n = 375) for IV.
  • Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors.
  • CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Registries
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Aged. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Japan. Male. Middle Aged. Models, Biological. Neoplasm Staging. Prognosis. Reproducibility of Results. Retrospective Studies. Surveys and Questionnaires. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166840.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res; 2010 Nov;30(11):4717-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
  • The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker.
  • PATIENTS AND METHODS: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma.
  • It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors.
  • CONCLUSION: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115930.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


34. Togashi K, Koike T, Emura I, Usuda H: [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results]. Kyobu Geka; 2008 Jul;61(7):519-22; discussion 522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results].
  • OBJECTIVE: Non-invasive lung cancers showed a good prognosis after limited surgery.
  • But it is still uncertain about invasive lung cancers.
  • We investigated the indications for limited surgery for small lung cancer tumors measuring 1 cm or less in diameter on preoperative computed tomography (CT).
  • METHODS: This study retrospectively analyzed of 1,245 patients who underwent complete resection of lung cancer between 1989 and 2004 in our hospital.
  • RESULTS: All diseases were detected by medical checkup, 52 % of the patients were not definitively diagnosed with lung cancer before surgery.
  • Adenocarcinoma was histologically diagnosed in 49 patients (79%).
  • Other histologic types included squamous cell carcinoma (8), large cell carcinoma (1), small cell carcinoma (1), carcinoid (2), and adenosquamous cell carcinoma (1).
  • There were 3 deaths from cancer recurrence, while there were no deaths in 14 patients with bronchioloalveolar carcinoma CONCLUSION: After limited surgery, non-invasive cancer showed good long-term results, while invasive cancer showed a recurrence rate of 2.3% to 79% even though the tumor measured 1 cm or less in diameter on preoperative CT.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616092.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, Tsuchiya E, Nakamura Y: ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res; 2005 Dec 15;65(24):11314-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.
  • Gene expression profile analysis of non-small cell lung cancers (NSCLC) and subsequent functional analyses revealed that human ANLN, a homologue of anillin, an actin-binding protein in Drosophila, was transactivated in lung cancer cells and seemed to play a significant role in pulmonary carcinogenesis.
  • Immunohistochemical staining of nuclear ANLN on lung cancer tissue microarrays was associated with the poor survival of NSCLC patients, indicating that this molecule might serve as a prognostic indicator.
  • Our data imply that up-regulation of ANLN is a common feature of the carcinogenetic process in lung tissue, and suggests that selective suppression of ANLN could be a promising approach for developing a new strategy to treat lung cancers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Contractile Proteins / metabolism. Lung Neoplasms / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. rhoA GTP-Binding Protein / metabolism
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Movement. Enzyme Activation. Female. Flow Cytometry. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged. Prognosis. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Survival Rate. Tissue Array Analysis. Tumor Cells, Cultured. Wound Healing

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357138.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Contractile Proteins; 0 / RNA, Small Interfering; 0 / anillin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


36. Sun Y, Lin H, Zhu Y, Feng J, Chen Z, Li G, Zhang X, Zhang Z, Tang J, Shi M, Hao X, Han H: [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):254-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients].
  • The aim of this study is to observe the clinical anticancer effect of Rg3 in combination with chemotherapy regimen NP (vinorelbine+cisplatin) in advanced non-small cell lung cancer (NSCLC).
  • Types of pathology: adenocarcinoma, 71; squamous cell carcinoma, 29; adenosquamous carcinoma, 8; others, 7.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172156.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Sanada H, Hayashi A, Tomimitsu S, Ikeda K, Nakanishi K, Hiyama J, Hidaka D, Sawamoto R, Miyagawa Y, Misumi Y, Fujii A, Nakatsubo S, Tsuru M, Omagari J, Koshizuka H: [Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2012-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer].
  • We have performed the clinical evaluations of preoperative induction chemoradiotherapy (CRTx) for 25 patients with non small-cell lung cancer (male: 19, female: 6, mean age: 66.4-year-old).
  • In the histological type of lung cancer, there were 12 patients of adenocarcinoma, 7 of squamous cell carcinoma, 1 of adenosquamous carcinoma, 1 of anaplastic carcinoma, and 4 of large cell carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037308.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Cappello F, Di Stefano A, David S, Rappa F, Anzalone R, La Rocca G, D'Anna SE, Magno F, Donner CF, Balbi B, Zummo G: Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer; 2006 Nov 15;107(10):2417-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The relation between smoking, chronic obstructive pulmonary disease (COPD), and lung cancer (LC) is an open field of investigation.
  • A higher frequency of adenocarcinoma has been reported in patients with COPD.
  • Heat shock proteins (Hsps) are implicated in tumoral cell growth and differentiation.
  • The aim of the present study was to investigate the expression of Hsp60 and Hsp10 in bronchial biopsies from smokers with COPD and in 10 lung cancer patients and to evaluate the association between Hsps expression and carcinogenetic steps of LC.
  • METHOD: An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory volume in 1 second [FEV(1)]: 53 +/- 19% [mean +/- SD]) patients with a history of smoking (53 +/- 34 pack/years) and in 10 patients with adenocarcinoma or adenosquamous carcinoma (ASC).
  • RESULTS.: In smokers with COPD, 10 out of 35 patients had a normal bronchial epithelium (NBE), 12 showed basal cell hyperplasia (BCH), 5 squamous metaplasia (SM), and 8 dysplasia (Dy).
  • CONCLUSIONS: The loss of Hsp60 and Hsp10 immunopositivity is related to the development and progression of bronchial cancer in smokers with COPD.
  • [MeSH-major] Carcinoma, Bronchogenic / diagnosis. Chaperonin 10 / metabolism. Chaperonin 60 / metabolism. Lung Neoplasms / diagnosis. Pulmonary Disease, Chronic Obstructive / complications. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Blotting, Western. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Disease Progression. Down-Regulation. Humans. Middle Aged. Prognosis. Respiratory Mucosa / pathology


39. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion


40. Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura A, Shibuya M, Nagashima M, Harris CC, Kudoh S: Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep; 2006 Mar;15(3):545-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
  • The ING1 gene is involved in the regulation of the cell cycle, senescence, and apoptosis and is a novel candidate tumor suppressor gene.
  • To determine whether an alteration in these genes plays a role in carcinogenesis and tumor progression in lung cancer, we screened 30 human lung cancer cell lines and 31 primary lung cancer tumors for mutations in these genes using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing.
  • We also examined the expression of ING1 and ING2 in lung cancer cell lines that either had or lacked a p53 mutation, and in a control bronchial epithelium cell line, using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • ING1 expression was up-regulated in all 7 lung cancer cell lines that had a p53 mutation, while the expression of ING2 was down-regulated in 6 of 7 lung cancer cell lines that had a p53 mutation.
  • These results suggest that the ING1 and ING2 genes have different roles in lung carcinogenesis and progression, and the ING2 gene may be an independent tumor suppressor candidate on p53.
  • [MeSH-major] Lung Neoplasms / pathology. Mutation. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Base Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. DNA Mutational Analysis. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins / genetics. Nuclear Proteins / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Cytoplasmic and Nuclear / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465410.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / ING1 protein, human; 0 / ING2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


41. Allen TC, Granville LA, Cagle PT, Haque A, Zander DS, Barrios R: Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung. Hum Pathol; 2007 Feb;38(2):220-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung.
  • A total of 201 non-small cell lung cancers (NSCLC) with long-term follow-up were immunostained with antibodies to GST-pi and GSH2 using standard immunostaining techniques.
  • Nuclear staining with GST-pi in greater than 10% of the cells was closely associated with decreased survival (P = .02) in stage I and II squamous cell carcinomas (n = 40).
  • Cytoplasmic GSH2 staining in greater than 80% of tumor cells was associated with a trend toward improved survival for stage I adenocarcinoma (P = .08) but did not show a relationship to survival for other histologic types of NSCLC.
  • GST-pi expression predicts prognosis in stage I and II squamous cell lung carcinoma, and GSH2 expression may indicate better survival in early stage adenocarcinoma of the lung.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Glutathione S-Transferase pi / biosynthesis. Glutathione Synthase / biosynthesis. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / enzymology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234469.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione S-Transferase pi; EC 6.3.2.3 / Glutathione Synthase
  •  go-up   go-down


42. Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N: Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins. Tumori; 2007 Sep-Oct;93(5):473-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
  • AIMS AND BACKGROUND: Lung cancer is one of the most common cancers and has became a predominant cause of cancer-related death throughout the world.
  • The k-ras codon 12 mutation, which is the most common lung cancer mutation, is found in 15 to 30% of all lung cancers.
  • Furthermore, the p53 gene has a very important role in the biological properties of tumor cells, and it is mutated in about 50% of non-small cell lung cancers.
  • METHODS: In the present study, we examined p53 gene mutations and k-ras codon 12 mutations from the tumor samples and surgical margins of 34 non-small-cell lung cancer patients.
  • Moreover, a k-ras codon 12 mutation was detected in both the primary tumor and the surgical margin tissues of 2 out of 34 patients (5.88%).
  • We think that different mechanisms related to other genes and individual genetic differences might play a role in cancer formation in our study group.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Protein p53 / genetics. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Codon / genetics. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Prognosis. Proto-Oncogene Proteins p21(ras). Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038880.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


43. Iwasaki A, Shirakusa T, Miyoshi T, Hamada T, Enatsu S, Maekawa S, Hiratsuka M: Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease. Thorac Cardiovasc Surg; 2006 Feb;54(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease.
  • BACKGROUND: Surgical resection may continue to offer the best chance of long-term survival for patients with non-small cell lung cancer (NSCLC).
  • METHODS: We retrospectively reviewed 142 non-small cell lung cancer patients with T1-3 N2 in whom a curative approach had been attempted between January 1994 and December 2003.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Analysis of Variance. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Pulmonary Surgical Procedures. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome


44. Lee HS, Kim MS, Lee JM, Kim SK, Kang KW, Zo JI: Intrathoracic gastric emptying of solid food after esophagectomy for esophageal cancer. Ann Thorac Surg; 2005 Aug;80(2):443-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathoracic gastric emptying of solid food after esophagectomy for esophageal cancer.
  • BACKGROUND: Information on the function of the intrathoracic stomach after esophageal resection for esophageal cancer is limited.
  • METHODS: Between February 2003 and August 2003, intrathoracic gastric emptying of solid food was evaluated by radioisotope in 56 of the patients who underwent esophageal replacement surgery with the stomach for esophageal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Gastric Emptying
  • [MeSH-minor] Carcinoma, Adenosquamous / surgery. Female. Food. Humans. Male. Middle Aged. Stomach / physiology. Stomach / surgery. Thoracic Cavity

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Aug;80(2):447-8 [16039183.001]
  • (PMID = 16039182.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Robledo-Ogazón F, Vargas-Rivas A, Hernández-Ramírez DA, Castellanos-Juárez JC: [Congenital diaphragmatic adult hernia. Case report]. Cir Cir; 2008 Jan-Feb;76(1):61-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hernia diafragmática congénita en el adulto. Informe de un caso.
  • Diagnosis is incidental or when it becomes symptomatic.
  • Our objective was to offer the general surgeon a differential diagnosis for presence of noncardiac thoracic pain in the adult.
  • CLINICAL CASE: We present the case of a 78-year-old female with cardiorespiratory and digestive symptoms of slight intensity and managed for many years as hypertensive cardiopathy and dyspeptic syndrome until she was admitted to our service with severe epigastric pain.
  • Primary repair of the diaphragm and cholecystectomy were performed, confirming gallbladder cancer.
  • It is important that the surgeon establishes an etiological diagnosis in order to offer appropriate treatment.
  • CONCLUSIONS: Congenital diaphragmatic hernia in the adult is rarely suspected in the differential diagnosis of noncardiac thoracic pain.
  • The surgeon must keep this in mind, especially in patients of advanced age, even when cardiac and/or gastrointestinal diagnosis is confirmed.
  • [MeSH-minor] Age of Onset. Aged. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Cholecystectomy. Cholelithiasis / complications. Cholelithiasis / surgery. Cough / etiology. Diagnostic Errors. Dyspepsia / diagnosis. Female. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / radiography. Gallbladder Neoplasms / surgery. Gastroesophageal Reflux / etiology. Heart Diseases / diagnosis. Hernia, Diaphragmatic / complications. Hernia, Diaphragmatic / diagnosis. Hernia, Diaphragmatic / epidemiology. Humans. Incidental Findings. Lung Diseases / diagnosis. Tomography, X-Ray Computed


46. Yatabe Y, Takahashi T, Mitsudomi T: Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res; 2008 Apr 1;68(7):2106-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.
  • Both mutation and amplification of epidermal growth factor receptor (EGFR) in lung cancers have been reported in association with clinical responses to tyrosine kinase inhibitors.
  • We have reported evidence implicating mutation specifically in the "terminal respiratory unit" type of adenocarcinoma, which is characterized by expression of thyroid transcription factor 1, a lineage marker of peripheral airway cells.
  • However, little is known about the role of gene amplification in the molecular progression of lung adenocarcinoma.
  • In this study, we examined the topographical distribution of amplification in three microdissected portions each of 48 individual lung cancers with confirmed mutations.
  • Gene amplification was found in 11 lung cancers.
  • We also examined 17 precursor lesions and 21 in situ lung adenocarcinomas, and found that only one in situ carcinoma harbored gene amplification.
  • Taken together, our results show that mutation occurs early in the development of lung adenocarcinoma, and that amplification may be acquired in association with tumor progression.
  • [MeSH-major] Gene Amplification. Genes, erbB-1. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Mutation
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Metastasis


47. Liu HH, Jauregui M, Zhang X, Wang X, Dong L, Mohan R: Beam angle optimization and reduction for intensity-modulated radiation therapy of non-small-cell lung cancers. Int J Radiat Oncol Biol Phys; 2006 Jun 1;65(2):561-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beam angle optimization and reduction for intensity-modulated radiation therapy of non-small-cell lung cancers.
  • PURPOSE: To optimize beam angles and reduce the number of beams used for intensity-modulated radiation therapy (IMRT) of non-small-cell lung cancer (NSCLC).
  • RESULTS: Each anatomic structure, e.g., tumor or lung, had its own preferred beam angles.
  • CONCLUSIONS: Use of fewer beams (e.g., five) for lung IMRT could result in acceptable plan quality but improved treatment efficiency.
  • [MeSH-major] Algorithms. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radiotherapy. Humans. Technology, Radiologic / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690438.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 74043
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Massard G, Ducrocq X, Kochetkova EA, Porhanov VA, Riquet M: Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg; 2006 Jul;30(1):164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study.
  • OBJECTIVE: This study compares accuracy of sampling versus formal node dissection in patients with primary lung cancer.
  • PATIENTS AND METHODS: During a 4-month period, 208 consecutive patients (172 men, 36 women) without bulky disease underwent resection for primary lung cancer in three centers.
  • There were 108 squamous cell carcinomas, 621 adenocarcinomas, 18 bronchoalveolar carcinomas, 8 large cell carcinomas, 4 adenosquamous carcinomas and 8 neuroendocrine carcinomas.
  • CONCLUSION: Radical mediastinal dissection is a mandatory adjunct to resection for lung cancer with curative attempt.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jan;31(1):142-3; author reply 143-4 [17092737.001]
  • (PMID = 16725340.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


49. Chang YL, Wu CT, Lee YC: Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg; 2007 Sep;134(3):630-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients.
  • OBJECTIVES: According to our previous study, the concurrent detection of p53 and epidermal growth factor receptor mutations significantly improves the clonality assessment and impact management of patients with multiple primary lung cancer.
  • METHODS: A database of 1651 patients was evaluated for unilateral and bilateral synchronous multiple primary lung cancers.
  • RESULTS: The 5-year survival for all synchronous multiple primary lung cancers was 35.3%.
  • Notably, lymph node metastasis, extranodal extension, vascular invasion, tumors with adenosquamous carcinoma or different histology, and poor survival were observed.
  • CONCLUSION: An aggressive surgical approach is safe and justified in patients with synchronous multiple primary lung cancers and node-negative diseases.
  • The status of this particular form of non-small cell lung cancers might be considered in the conventional TNM staging system for more accurate prediction of patient prognosis.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Cardiovasc Surg. 2008 Aug;136(2):542
  • (PMID = 17723810.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J: [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Feb;45(2):166-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Herpes Zoster / complications. Respiratory Paralysis / etiology
  • [MeSH-minor] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Middle Aged. Pneumonectomy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352174.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


51. Okamoto T, Maruyama R, Suemitsu R, Aoki Y, Wataya H, Kojo M, Ichinose Y: Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg; 2006 Aug;5(4):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the histological subtype in completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC), which includes several different histological subtypes, is usually treated by the same strategy.
  • However, the biological behavior of each cell type appears to be different.
  • We retrospectively reviewed the clinical records of 1119 consecutive NSCLC patients who underwent a complete resection, in order to investigate whether a histological cell type is a powerful prognostic factor.
  • The overall 5- and 10-year survivals of the patients with adenocarcinoma (AD), squamous cell carcinoma (SQ), large cell carcinoma (LA), and adenosquamous cell carcinoma (AS) were 54.2 and 40.2%, 51.6 and 30.3%, 40.9 and 18.7%, and 35.1 and 30.1%, respectively.
  • The AD patients had a significantly better survival than the non-AD patients in Stage I (P=0.0004), whereas the SQ patients had a better survival than the non-SQ patients in Stage II (P=0.018).
  • A multivariate survival analysis indicated the AD patients to have a significantly better survival than the SQ patients in Stage IA (P=0.04), while the SQ patients had a better survival than the AD patients in Stage II (P=0.03).
  • These above observations suggest that the prognosis after complete resection is different between adenocarcinoma and squamous cell carcinoma in Stage IA and II.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670594.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Cilli A, Ozkaynak C, Onur R, Erogullari I, Ogus C, Cubuk M, Arslan G, Ozdemir T: Lung cancer detection with low-dose spiral computed tomography in chronic obstructive pulmonary disease patients. Acta Radiol; 2007 May;48(4):405-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer detection with low-dose spiral computed tomography in chronic obstructive pulmonary disease patients.
  • PURPOSE: To determine whether low-dose spiral computed tomography (LDCT) can improve the lung cancer detection rate in chronic obstructive pulmonary disease (COPD) subjects.
  • MATERIAL AND METHODS: From October 1999 to December 2003, 374 COPD patients underwent LDCT for lung carcinoma screening.
  • RESULTS: On the baseline spiral CT scan, 132 of 374 patients (35.2%) had at least one non-calcified nodule that required periodic follow-up with CT scans.
  • Of the 374 COPD subjects, nine patients with primary lung cancer (2.4%) were detected: six were squamous cell carcinomas, two were small-cell lung carcinomas (SCLC), and one was adenosquamous carcinoma.
  • One subject with stage IA squamous cell carcinoma received radiotherapy, as pulmonary function was severely impaired.
  • CONCLUSION: LDCT increases early lung carcinoma detection rate in COPD patients, but pulmonary function impairment may reduce its benefit.
  • [MeSH-major] Carcinoma / radiography. Lung Neoplasms / radiography. Pulmonary Disease, Chronic Obstructive / complications. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bronchoscopy. Calcinosis / radiography. Carcinoma, Adenosquamous / radiography. Carcinoma, Small Cell / radiography. Carcinoma, Squamous Cell / radiography. Female. Follow-Up Studies. Humans. Male. Mass Screening. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiation Dosage. Solitary Pulmonary Nodule / radiography. Sputum / cytology. Thoracic Surgery, Video-Assisted


53. Kobashi Y, Mouri K, Fukuda M, Yoshida K, Miyashita N, Niki Y, Nakata M, Mikio O: [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities]. Nihon Kokyuki Gakkai Zasshi; 2005 Jan;43(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities].
  • A 68-year-old man was admitted to our hospital because of continuous cough of three months duration and for investigation of a thin-wall cavitary lesion (> 3 cm) in the right upper lung field.
  • A histological diagnosis of pulmonary adenocarcinoma was obtained by bronchoscopic examination, and he was transferred to the Department of Thoracic Surgery where a right upper lobectomy was performed.
  • Most of the surrounding cavity consisted of the components of a well differentiated squamous cell carcinoma with keratinization and slightly different components of a poorly differentiated adenocarcinoma with mucous production.
  • The final diagnosis was pulmonary adenosquamous cell carcinoma and the postoperative histological classification was T2N2M0 (Stage 3A) because of metastasis to the lymph nodes (#4 and #11).
  • Although squamous cell carcinoma has been reported to be the histological type, tending to form thin-wall cavities among patients with lung cancer reported to be squamous cell carcinoma, recently an increasing number of such cavities have been reported among patients with pulmonary adenocarcinoma.
  • Herein, we have reported a rare case of histological diagnosis of pulmonary adenosquamous cell carcinoma with cavity formation.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704455.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Li B, Li Z, Zhang Y, Li Y, Wu W: [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):469-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung].
  • BACKGROUND: Adenosquamous carcinoma of the lung is a rare pathologic type of lung cancer.
  • The aim of this study is to explore the clinical features of adenosquamous carcinoma of the lung.
  • METHODS: A total of 115 patients with adenosquamous carcinoma of the lung were retrospectively analysed, who were diagnosed by operation and pathology.
  • There were 14 patients (12.17%) without any symptom and 16 patients had residual carcinoma at the resection margin (14.04%).
  • CONCLUSIONS: The incidence of adenosquamous carcinoma of the lung in young women (under 49 years, especially under 39 years) is rather high.
  • The residual carcinoma at the resection margin often occurs after routine operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176475.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


55. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P: Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol; 2009 Jan;4(1):12-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
  • BACKGROUND: Progression of non-small cell lung cancer (NSCLC) from early- to late-stage may signify the accumulation of gene mutations.
  • Mutation detection of multiple genes is limited by the low amount of deoxyribonucleic acid extracted from low-volume diagnostic lung biopsies.
  • Their low-volume lung biopsies underwent WGA before direct sequencing for epidermal growth factor receptor (EGFR), KRAS (rat sarcoma virus), p53, and CMET (mesenchymal-epithelial transition factor) mutations.
  • RESULTS: It is feasible for low-volume lung biopsies to undergo WGA for mutational analysis.
  • WGA may be used to expand starting deoxyribonucleic acid from low-volume lung biopsies for further analysis of advanced-stage NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-met / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Base Sequence. Biopsy. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. DNA, Neoplasm / genetics. Feasibility Studies. Female. Gene Amplification. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096301.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


56. Okwuosa TM, Williams KA: "Mass-ive" infarction: case report and review of myocardial metastatic malignancies. J Nucl Cardiol; 2008 Sep-Oct;15(5):719-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac metastases from lung cancer are rarely diagnosed ante mortem and usually cause no symptoms or signs.
  • In this case report cardiac metastasis from a primary adenosquamous cancer of the lung presented as myocardial infarction in a 61-year-old man.
  • His diagnosis was made and confirmed via multimodality imaging of the heart, which is also reviewed in depth.
  • [MeSH-major] Heart Neoplasms / secondary. Lung Neoplasms / pathology. Myocardial Infarction / pathology. Myocardium / pathology. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Heart J. 1988 Nov;116(5 Pt 1):1359-61 [3189152.001]
  • [Cites] Clin J Am Soc Nephrol. 2007 Mar;2(2):264-7 [17699423.001]
  • [Cites] Circulation. 1981 Feb;63(2):448-51 [7449067.001]
  • [Cites] Am Heart J. 1986 Dec;112(6):1297-303 [3788778.001]
  • [Cites] Arch Mal Coeur Vaiss. 2001 Dec;94(12):1423-6 [11828930.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):437-42 [1617593.001]
  • [Cites] Kokyu To Junkan. 1989 Apr;37(4):461-5 [2740646.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1456-9 [2306690.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Oct;135(4):645-7 [17011435.001]
  • [Cites] Eur Heart J. 1993 Sep;14 (9):1223-8 [8223737.001]
  • [Cites] Support Care Cancer. 2001 Jun;9(4):275-7 [11430424.001]
  • [Cites] Cardiology. 2005;103(1):53-4 [15528902.001]
  • [Cites] Australas Radiol. 2004 Sep;48(3):383-7 [15344991.001]
  • [Cites] Circulation. 1960 Sep;22:474-83 [13711211.001]
  • [Cites] Cardiol Clin. 2007 Feb;25(1):111-40, vi [17478243.001]
  • [Cites] Jpn Heart J. 1974 May;15(3):234-8 [4546955.001]
  • [Cites] Am J Med. 1986 Jan;80(1):108-12 [3942141.001]
  • [Cites] Cancer. 1972 Mar;29(3):799-808 [4501215.001]
  • [Cites] Circulation. 2005 Jul 26;112(4):e61-2 [16043650.001]
  • [Cites] Arch Pathol Lab Med. 1993 Oct;117(10):1027-31 [8215825.001]
  • [Cites] AMA Arch Intern Med. 1953 Feb;91(2):224-49 [13016041.001]
  • [Cites] AMA Arch Pathol. 1951 Jan;51(1):98-128 [14789340.001]
  • [Cites] Dis Chest. 1969 Mar;55(3):202-8 [5765189.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):439-49 [11259706.001]
  • [Cites] Chest. 2007 May;131(5):1569-72 [17494807.001]
  • [Cites] Circulation. 2005 Nov 22;112(21):e329-30 [16301348.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):195-201 [3411785.001]
  • [Cites] Magn Reson Imaging. 1998;16(1):91-5 [9436953.001]
  • [Cites] Cardiovasc Intervent Radiol. 2004 Sep-Oct;27(5):459-69 [15383848.001]
  • (PMID = 18761275.001).
  • [ISSN] 1532-6551
  • [Journal-full-title] Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  • [ISO-abbreviation] J Nucl Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


57. Takahama M, Yamamoto R, Nakajima R, Tsukioka T, Tada H: Pulmonary resection for lung cancer patients on chronic hemodialysis: clinical outcome and long-term results after operation. Interact Cardiovasc Thorac Surg; 2010 Aug;11(2):150-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection for lung cancer patients on chronic hemodialysis: clinical outcome and long-term results after operation.
  • The purpose of this study was to investigate the clinical characteristics of chronic hemodialysis (HD) patients with lung cancer who underwent pulmonary resection at the authors' hospital.
  • Subjects were 24 chronic HD patients (1.1%) from among 2178 patients who underwent pulmonary resection for lung cancer at our hospital between December 1994 and March 2009.
  • Histological diagnoses included squamous cell carcinoma in 12 patients, adenocarcinoma in nine, small cell carcinoma in two and adenosquamous carcinoma in one.
  • Cases of pulmonary resection for lung cancer in chronic HD patients were investigated.
  • [MeSH-major] Lung Neoplasms / surgery. Pneumonectomy. Renal Dialysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20513739.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, Okumura M, Miyaoka E, Fujii Y, Japanese Joint Committee for Lung Cancer Registration: Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study. J Thorac Oncol; 2010 Oct;5(10):1594-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
  • INTRODUCTION: Women with non-small cell lung cancer (NSCLC) are more likely to have better survival than men.
  • METHODS: In 2005, the Japanese Joint Committee for Lung Cancer Registration performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of patients who underwent resection for primary lung neoplasms in 1999.
  • Women had a higher incidence of adenocarcinoma (p < 0.001) and stage IA disease (p < 0.001) than men.
  • According to histology, the overall survival of women was significantly better than that of men for both adenocarcinoma (5-YSR, 77.7 versus 61.9%, p = 0.0000) and nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p = 0.035).
  • In adenocarcinoma, women had a significantly better prognosis than men for pathologic stage I/II disease.
  • CONCLUSIONS: Women with NSCLC, especially with an adenocarcinoma histology, had better survival than men.
  • Women were more likely to have adenocarcinoma and stage IA disease, which might account for the better prognosis in women.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / mortality. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality


59. Yakut T, Schulten HJ, Demir A, Frank D, Danner B, Egeli U, Gebitekin C, Kahler E, Gunawan B, Urer N, Oztürk H, Füzesi L: Assessment of molecular events in squamous and non-squamous cell lung carcinoma. Lung Cancer; 2006 Dec;54(3):293-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of molecular events in squamous and non-squamous cell lung carcinoma.
  • Although considerable knowledge exists on the tumor biology of lung cancer, there is still a need to assess molecular events for the clinical management of the disease.
  • We studied the pattern of chromosomal imbalances in 45 non-small cell lung carcinomas (NSCLC) by comparative genomic hybridization (CGH) and correlated the results with clinicopathological features including immunohistochemical (IHC) expression of the epidermal growth factor receptor (EGFR).
  • Twenty-one tumors were squamous cell carcinomas (SCC) and 24 non-squamous cell lung carcinomas (NSCC) comprising 9 adenocarcinomas (ADC), 9 large cell carcinomas (LCC), 4 sarcomatoid carcinomas and 2 adenosquamous carcinomas.
  • In conclusion, the present study contributes to the molecular biological characterization of NSCLC histological subtypes and through evaluation of molecular events to the recently emergent focus on novel markers for lung cancer treatment.
  • [MeSH-major] Carcinoma / genetics. Carcinoma, Squamous Cell / genetics. Genomic Instability. Lung Neoplasms / genetics


60. de Jong WK, Schaapveld M, Blaauwgeers JL, Groen HJ: Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours. Thorax; 2008 Dec;63(12):1096-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All tumours originating from the trachea, bronchus and lung recorded in the Netherlands Cancer Registry were included.
  • Based on ICD-O morphology codes, five major subgroups were constructed: squamous carcinoma (SC), adenocarcinoma (AC), large cell (undifferentiated) carcinoma (LC), small cell lung cancer (SCLC) and other (including uncommon tumours).
  • Since 1996, a stage shift was observed with fewer patients in stage I and more patients in stage IV at diagnosis.
  • The incidence of adenosquamous carcinoma decreased from 0.6 to 0.29/100 000 (p<0.001).
  • The incidence of non-smoking-related uncommon tumours remained constant.
  • [MeSH-major] Bronchial Neoplasms / epidemiology. Lung Neoplasms / epidemiology. Rare Diseases / epidemiology. Tracheal Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18678702.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Yang F, Chen H, Xiang J, Zhang Y, Zhou J, Hu H, Zhang J, Luo X: Relationship between tumor size and disease stage in non-small cell lung cancer. BMC Cancer; 2010;10:474
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between tumor size and disease stage in non-small cell lung cancer.
  • The objective is to assess the relationship between tumor size and disease stage distribution in non-small cell lung cancer (NSCLC).
  • METHODS: We conducted a retrospective analysis of 917 cases of NSCLC that were resected in the Cancer Hospital of Fudan University and Shanghai Sixth Hospital between January 2000 and February 2009.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


62. Balcer-Kubiczek EK, Attarpour M, Edelman MJ: The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines. Cancer Chemother Pharmacol; 2007 May;59(6):781-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines.
  • PURPOSE: The present study was designed to investigate the ability of N-[4-(5-bromo-2-pyrimidyloxy)-3-methylphenyl]-(dimemethylamino)-benzoylphenylurea (dimemethylamino benzoylphenylurea;.
  • BPU) to sensitize cells to radiation and to examine the relationship between phenotype versus survival, DNA damage, apoptosis, or cell cycle progression in non-small cell lung cancer (NSCLC) cell lines.
  • METHODS: Asynchronous cultures of three NSCLC (phenotype) lines, A549 (adenocarcinoma), NCI-H226 (squamous) and NCI-H596 (adenosquamous) were used.
  • Cells were treated for 24 h with BPU at various concentrations (0-10 microM) to obtain drug doses for inhibiting cell survival by approximately 50% (IC50).
  • Cell survival was determined by a colony-forming ability assay.
  • The effect of BPU on the cell cycle distribution and induction of apoptosis were measured by flow cytometry-based assays.
  • RESULTS: BPU (1.5 microM) for 24 h produced approximately 50% cell survival.
  • BPU and X-irradiation were synergistic in the three cell lines at survival levels of 20-50%.
  • Flow cytometry analysis of replicate experiments with BPU (1.5 microM for 24 h) showed that BPU blocked cell progression at S and/or G2/M.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Methylurea Compounds / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Survival / drug effects. Combined Modality Therapy. DNA Damage / drug effects. Humans. Radiation-Sensitizing Agents / therapeutic use. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957930.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Methylurea Compounds; 0 / Radiation-Sensitizing Agents; 0 / dimethyl benzoylphenyl urea
  •  go-up   go-down


63. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax; 2008 Apr;63(4):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas.
  • This study was undertaken to investigate the possibility that overexpression of S100A7 protein might be detected in the sera of patients with lung cancer.
  • METHODS: RNA and protein levels of S100A7 were examined in 60 pairs of frozen lung cancer tissues by RT-PCR and western blot.
  • The specific expression of this protein and its cellular distribution were investigated in 145 paraffin embedded lung cancer samples, six benign lung disease and 21 normal lung tissues by immunohistochemistry.
  • The S100A7 protein level was further analysed in serum from 112 patients with lung cancer, 20 with benign lung diseases and 31 healthy individuals by ELISA.
  • RESULTS: Specific expression of both S100A7 mRNA and protein was found in squamous cell carcinomas, adenosquamous carcinomas and large cell lung carcinomas, whereas neither was detected in adenocarcinomas or paired non-cancerous lung tissues.
  • Further immunohistochemical analysis identified positive staining of S100A7 only in squamous cell carcinomas and large cell lung carcinomas, but not in other subtypes of lung cancer and normal lung tissues.
  • Weak expression was also found in the inflammatory cells of benign lung diseases.
  • Our most important finding is that elevated S100A7 protein could be detected in the sera of patients with squamous cell carcinomas.
  • CONCLUSION: S100A7 was only expressed in squamous cell carcinomas and large cell lung carcinomas and an increase in the level of S100A7 protein in serum may serve as a potential marker for lung cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Calcium-Binding Proteins / metabolism. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364444.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


64. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med; 2006 Dec;3(12):e486
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
  • However, DNA methylation markers that are highly specific and sensitive for common tumors would be useful for the early detection of cancer, and those required for the malignant phenotype would identify pathways important as therapeutic targets.
  • METHODS AND FINDINGS: In an effort to identify new cancer-specific methylation markers, we employed a high-throughput global expression profiling approach in lung cancer cells.
  • We identified 132 genes that have 5' CpG islands, are induced from undetectable levels by 5-aza-2'-deoxycytidine in multiple non-small cell lung cancer cell lines, and are expressed in immortalized human bronchial epithelial cells.
  • As expected, these genes were also expressed in normal lung, but often not in companion primary lung cancers.
  • Methylation analysis of a subset (45/132) of these promoter regions in primary lung cancer (n = 20) and adjacent nonmalignant tissue (n = 20) showed that 31 genes had acquired methylation in the tumors, but did not show methylation in normal lung or peripheral blood cells.
  • We studied the eight most frequently and specifically methylated genes from our lung cancer dataset in breast cancer (n = 37), colon cancer (n = 24), and prostate cancer (n = 24) along with counterpart nonmalignant tissues.
  • We found that seven loci were frequently methylated in both breast and lung cancers, with four showing extensive methylation in all four epithelial tumors.
  • CONCLUSIONS: By using a systematic biological screen we identified multiple genes that are methylated with high penetrance in primary lung, breast, colon, and prostate cancers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jan 15;55(2):220-3 [7812947.001]
  • [Cites] Cancer. 1995 May 1;75(9):2400-1 [7712451.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4268-72 [7671234.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):56-71 [16644104.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:32-91 [8806092.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):766-74 [9833771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):166-72 [15671542.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):273-82 [15713962.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3654-60 [15897561.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):275-85 [16226703.001]
  • [Cites] Int J Cancer. 2005 Dec 10;117(5):738-45 [15981206.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):4067-8 [16141249.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):216-22 [16408038.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):653-8 [16423993.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):149-53 [16444255.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3105-9 [11306494.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):514-9 [11839671.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4822-9 [12101420.001]
  • [Cites] Genet Epidemiol. 2002 Jun;23(1):70-86 [12112249.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:245-54 [12610534.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1114-21 [12615730.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1596-601 [12670910.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:22-7 [12724209.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3104-9 [15131050.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3465-73 [15150099.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Hum Mol Genet. 2004 Sep 1;13(17):1969-78 [15254011.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5982-7 [15342377.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6410-5 [15374948.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7669-78 [15361840.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Oncogene. 1992 Jan;7(1):171-80 [1311061.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):183-9 [7522041.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):28-30 [7805035.001]
  • [CommentIn] PLoS Med. 2006 Dec;3(12):e479 [17194184.001]
  • (PMID = 17194187.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE5816
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA84971
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNA1 protein, human; 0 / Cyclin A; 0 / Cyclin A1; 0 / DNA-Binding Proteins; 0 / MSX1 Transcription Factor; 0 / MSX1 protein, human; 0 / Transcription Factors; 148814-46-4 / BNC1 protein, human; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC1716188
  •  go-up   go-down


65. Simi L, Venturini G, Malentacchi F, Gelmini S, Andreani M, Janni A, Pastorekova S, Supuran CT, Pazzagli M, Orlando C: Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. Lung Cancer; 2006 Apr;52(1):59-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
  • In the present study we investigated with quantitative RT-PCR the expression of CA IX mRNA in 93 non-small cell lung carcinomas (NSCLC) and in their paired not affected tissues.
  • The increase of CA IX mRNA expression in cancer tissues was significantly correlated to the increase of corresponding protein, as determined with conventional immunoblotting (p = 0.027).
  • Whereas CA IX mRNA expression was not associated to any clinical-pathological parameters in our patients, global survival analysis of cancer-related death revealed that high expression of CA IX mRNA predicted unfavorable outcome (p = 0.001) and shorter disease free survival interval (p = 0.004).
  • Finally we demonstrated that CA IX expression was not able to discriminate different survival probability in adenocarcinomas, whereas the same parameter was highly predictive in squamous (p = 0.03) and adenosquamous cell carcinomas (p = 0.001).
  • [MeSH-major] Antigens, Neoplasm / genetics. Carbonic Anhydrases / genetics. Gene Expression Regulation, Enzymologic. Lung Neoplasms / genetics. RNA, Messenger / metabolism
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Gene Expression Regulation, Neoplastic. Humans. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16513206.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


66. Zhang BS, Yu CH, Zhang YM, Yu JQ, Zhou NK: [Prognostic analysis of partial atrium or large blood vessel resection for treatment of locally advanced lung cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov;30(11):2509-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of partial atrium or large blood vessel resection for treatment of locally advanced lung cancer].
  • OBJECTIVE: To explore the value of partial atrium or large blood vessel resection for the treatment of locally advanced lung cancer.
  • METHODS: Thirty-five patients with locally advanced lung cancer (T(4)N(0)-N(2)M(0)) underwent lobectomy or pneumonectomy combined with intrapericardial vascular management or partial resection of the atrium.
  • Of the 35 patients , 15 underwent left pneumonectomy combined with partial resection of the left atrium, 3 had pneumonectomy and partial resection of pulmonary artery trunk, 11 received right pneumonectomy and partial resection of the left atrium, 3 had middle and lower lobectomies and partial resection of the left atrium, and 3 underwent right upper lobectomy, partial resection of the superior vena cava and replacement of artificial blood vessel.
  • Pathologically, 27 patients had squamous carcinoma, 3 had adenocarcinoma, 3 had adenosquamous carcinoma and 2 had large cell carcinoma.
  • CONCLUSION: Pneumonectomy or lobectomy combined with intrapericardial vascular management or partial resection of the atrium can enhance the possibility of radical resection of locally advanced lung cancer and increase the long term survival rate.
  • [MeSH-major] Heart Atria / surgery. Lung Neoplasms / surgery. Vena Cava, Superior / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097419.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol; 2009 Jan;4(1):5-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
  • For lung cancer, MET gene amplification is reported to occur in a subset of adenocarcinomas.
  • Although somatic mutations of MET in lung adenocarcinomas are rare, all but one of those reported so far entail a splice mutation deleting the juxtamembrane domain for binding the c-Cbl E3-ligase; normally such binding leads to ubiquitination and receptor degradation, and loss of this domain leads to MET activation.
  • The purpose of this study was to clarify in the role of MET activation in lung carcinogenesis.
  • MATERIALS AND METHODS: MET gene copy number was determined by real-time quantitative polymerase chain reaction in 187 of the patients with lung cancer and the MET gene splice mutation deleting the juxtamembrane domain was examined by direct sequencing in 262.
  • [MeSH-major] Alternative Splicing. Gene Amplification. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics. Small Cell Lung Carcinoma / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Base Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Gene Dosage. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Pneumonectomy. Prognosis. Protein Structure, Tertiary. Proto-Oncogene Proteins c-cbl / metabolism. Proto-Oncogene Proteins c-met. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics. Sequence Deletion. Tumor Cells, Cultured. Ubiquitin-Protein Ligases / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096300.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.6.5.2 / ras Proteins; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


68. Abe A, Yamada H: Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells. Anticancer Drugs; 2009 Jun;20(5):373-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells.
  • In this study, harmol and harmalol, which are beta-carboline alkaloids, were examined for their antitumor effect on human lung carcinoma cell lines, and structure-activity relationship was also investigated.
  • In contrast, harmalol had negligible cytotoxicity in three cell lines.
  • In conclusion, our results showed that the harmol could cause apoptosis-inducing effects in human lung H596 cells through caspase-8-dependent pathway but independent of Fas/Fas ligand interaction.
  • [MeSH-major] Antigens, CD95 / physiology. Apoptosis / drug effects. Carcinoma, Non-Small-Cell Lung / pathology. Caspase 8 / drug effects. Fas Ligand Protein / physiology. Harmaline / analogs & derivatives. Harmine / analogs & derivatives. Lung Neoplasms / pathology. Neoplasm Proteins / drug effects
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Caspase 3 / metabolism. Caspase 9 / metabolism. Cell Line, Tumor / drug effects. Cell Line, Tumor / enzymology. Cell Line, Tumor / pathology. Enzyme Activation / drug effects. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. HARMALINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318910.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Neoplasm Proteins; 2NQN80556Q / harmalol; 487-03-6 / harmol; 4FHH5G48T7 / Harmine; CN58I4TOET / Harmaline; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


69. Nishio M, Matsuda M, Ohyanagi F, Sato Y, Okumura S, Tabata D, Morikawa A, Nakagawa K, Horai T: Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy. Lung Cancer; 2005 Aug;49(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-five patients with advanced non-small cell lung cancer received an antipyrine test and were treated with docetaxel and cisplatin.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antipyrine / pharmacokinetics. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adolescent. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Cisplatin / administration & dosage. Cytochrome P-450 Enzyme System / metabolism. Disease Progression. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Neutropenia / drug therapy. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16022919.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Taxoids; 15H5577CQD / docetaxel; 9035-51-2 / Cytochrome P-450 Enzyme System; Q20Q21Q62J / Cisplatin; T3CHA1B51H / Antipyrine
  •  go-up   go-down


70. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.
  • BACKGROUND: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the biological behavior and clinicopathological characteristics have not yet been thoroughly described.
  • METHOD: This study reviewed the patient charts of 11 (1.6%) ADSQ cases among 779 patients with primary lung cancer who underwent a lung resection.
  • Five patients had coexistent double cancer including 2 gastric, 1 rectal, 1 prostate and 1 bladder cancer.
  • ADSQ was found less frequently in males than squamous cell carcinoma (SQ).
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • ADSQ had a significantly correlation with double cancer (ADSQ vs. non- ADSQ p = 0.03).
  • A multivariate analysis showed no significant prognostic difference between the patients with ADSQ and non- ADSQ.
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.
  • However, surgeons must be cautious of any coexistent double cancer because approximately half of all patients with ADSQ of the lung have double cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


71. Yi L, Wang Y: [Mixed prostatic carcinoma: a report of 5 patients and literature review]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;34(7):646-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed prostatic carcinoma: a report of 5 patients and literature review].
  • OBJECTIVE: To improve the awareness of rare mixed prostatic carcinoma.
  • METHODS: We reviewed the clinical data of 5 patients with prostatic mixed tumor and relevant literature to explore diagnosis and treatment for it.
  • RESULTS: Patient 1 with mixed small cell carcinoma and adenocarcinoma of the prostate who underwent transurethral electrovaporization of the prostate (TUVP) and flumamide therapy died of lung metastasis 7 months later.
  • Patient 2 with mixed small cell carcinoma and adenocarcinoma of the prostate who underwent TUVP and bilateral testicular resection died of lung metastasis 10 months later.
  • Patient 3 with adenosquamous carcinoma of the prostate who underwent TUVP, radiation therapy and flumamide therapy died of multiple organ failure 8 months later because of the lung, liver, and multiple bone metastasis.
  • Patient 4 with prostatic adenosquamous carcinoma who underwent cystoprostatectomy combined with urinary diversion has already survived for 1 year.
  • Patient 5 with prostatic carcinosarcoma who underwent cystoprostatectomy, urinary diversion, pelvic lymphadenectomy, and radiation therapy died of lung metastasis 13 months later.
  • CONCLUSION: Mixed prostatic carcinoma is quite aggressive with bad prognosis.
  • Its diagnosis relies on detailed pathological examination and immunohistochemical techniques.
  • Patients with prostate adenocarcinoma should be followed up timely after endocrine treatment or radiotherapy.
  • Radical surgery is most effective for mixed prostatic carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Small Cell / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648679.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


72. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • Chest X-ray revealed multiple emphysematous bullae in both lungs and a tumor shadow in the right upper lobe.
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • This case suggests the possibility that von Recklinghausen's disease associated with emphysematous bullae is a risk factor for lung cancer.
  • Although von Recklinghausen's disease is reportedly associated with various malignant tumors, it is quite rare for von Recklinghausen's disease to be associated with triple non-neurogenic tumors.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Pulmonary Emphysema / complications. Pulmonary Emphysema / diagnosis. Pulmonary Emphysema / pathology. Risk Factors


73. Tsuchida M, Umezu H, Hashimoto T, Shinohara H, Koike T, Hosaka Y, Eimoto T, Hayashi JI: Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer; 2008 Dec;62(3):321-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the role of KIT expression in thymic carcinoma is not fully understood.
  • RESULTS: KIT- and CD5-positive staining was observed only in thymic carcinoma.
  • Percentage of positive staining was 100% in squamous cell carcinoma, with no positive staining in other histologies, including atypical carcinoid.
  • Mutation analysis of the KIT gene was performed in 11 squamous cell carcinomas, 1 adenocarcinoma and 1 adenosquamous cell carcinoma.
  • CONCLUSIONS: Squamous cell carcinoma of the thymus frequently expressed KIT and CD5 proteins, whereas other tumors did not.
  • Unlike GIST, overexpression of KIT does not necessarily indicate gene mutation in thymic carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Mutation / genetics. Proto-Oncogene Proteins c-kit / genetics. Thymoma / genetics. Thymus Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486988.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


74. Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA: Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer; 2008 Jul 22;99(2):245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
  • Somatic mutations of LKB1 tumour suppressor gene have been detected in human cancers including non-small cell lung cancer (NSCLC).
  • In this study we evaluated tumour specimens from 310 patients with NSCLC including those with adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma histologies.
  • They tended to occur more commonly in adenocarcinomas (13%) than in squamous cell carcinomas (5%) (P=0.066).

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 1;60(3):546-8 [10676634.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1747-51 [17711506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7001-3 [12460919.001]
  • [Cites] Expert Rev Mol Diagn. 2003 Jul;3(4):471-9 [12877386.001]
  • [Cites] Mol Cancer Ther. 2004 Apr;3(4):465-72 [15078990.001]
  • [Cites] Oncogene. 2004 May 13;23(22):4037-40 [15021901.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5084-91 [15077168.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2087-90 [9605748.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):677-81 [10079245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9248-51 [10430928.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Hum Mutat. 2005 Oct;26(4):291-7 [16110486.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8 [16467085.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1700-4 [16505411.001]
  • [Cites] J Med Genet. 2006 May;43(5):e18 [16648371.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3209-15 [16707622.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s [16857820.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5911-8 [17384680.001]
  • [Cites] Hum Mutat. 2001 Nov;18(5):397-410 [11668633.001]
  • (PMID = 18594528.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA114465; United States / NCI NIH HHS / CA / 1R01CA114465-01; United States / NCI NIH HHS / CA / P20CA90578-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.1.- / STK11 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2480968
  •  go-up   go-down


75. Kawamura T, Kanno R, Fujii H, Suzuki T: Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma. Pathobiology; 2005;72(5):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma.
  • OBJECTIVE: A key enzyme of fatty acid synthesis, fatty acid synthase (FAS), is expressed in human cancers, including squamous-cell carcinoma of the lung, and long-chain fatty acids are intracellularly transported and/or taken up from blood by fatty-acid-binding proteins (FABPs).
  • Since the liver-type (L-) FABP, a member of the FABPs, is detected in a subset of gastric adenocarcinomas, the expression of FAS, L-FABP and vascular endothelial growth factor (VEGF) was investigated in human lung carcinomas to elucidate the mechanisms of production and transportation of fatty acid(s) in cancer.
  • METHODS: Expression of L-FABP, FAS and VEGF in 199 surgically resected lung carcinomas was examined immunohistochemically.
  • RESULTS: L-FABP was detected in 60% (120 of 199) of the lung carcinoma cases; detection was increased in large-cell carcinoma (80%) and adenosquamous carcinoma (83%), but low in squamous-cell carcinoma (47%) and in small-cell carcinoma (57%).
  • CONCLUSIONS: L-FABP, FAS and VEGF are highly expressed in human lung cancer, and expression of L-FABP is associated with that of VEGF but not that of FAS, suggesting that L-FABP might be involved in the uptake of fatty acid(s) from the bloodstream.
  • [MeSH-major] Carcinoma / metabolism. Fatty Acid Synthases / metabolism. Fatty Acid-Binding Proteins / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374067.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / FABP1 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


76. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M, University of Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer; 2009 Apr 15;115(8):1723-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
  • BACKGROUND: The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene resulting from the chromosome inversion inv(2)(p21;p23) recently was identified in nonsmall cell lung cancer (NSCLC).
  • METHODS: EML4-ALK was investigated in 266 resected primary NSCLC, including adenocarcinomas (AD), lymphoepithelioma-like carcinomas, squamous cell carcinomas, mucoepidermoid carcinomas, and adenosquamous carcinomas, by reverse transcriptase-polymerase chain reaction and was verified by sequencing.
  • There were 11 ADs and 2 unusual carcinomas with mixed squamous and glandular components.
  • Immunohistochemistry demonstrated diffuse ALK fusion proteins in the tumor cell cytoplasm.
  • Patients who had EML4-ALK-positive AD had a younger median age (P = .018) compared with patients who did not have the fusion gene.
  • The authors concluded that EML4-ALK may be useful for predicting the potential response to ALK inhibitors as a therapeutic option for patients with lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, ras. Lung Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Receptor, Epidermal Growth Factor / genetics. Smoking


77. Tanaka T, Sekimura A, Tanaka H, Tonegawa K, Ogawa K, Haneda H: [Gallbladder metastasis of large cell lung cancer]. Kyobu Geka; 2009 Nov;62(12):1069-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder metastasis of large cell lung cancer].
  • A man, who received right upper lobectomy of the lung due to stage IIB large cell carcinoma 7 and half years ago, visited our hospital complaining of right upper abdominal pain.
  • Pathological diagnosis was adenosquamous cell carcinoma After 1 year and 4 months later, left adrenal gland tumor was found by CT scan, and the surgery was conducted.
  • Pathologically, it was diagnosed as metastasis from lung cancer.
  • By reevaluation of pathology of the gallbladder, the tumor was found to have similar component of resected lung cancer, suggesting the possibility of the tumor to be metastatic.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Gallbladder Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894573.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Zhao S, Shao K, Ye B, Liu X, Cheng G, Sun K, Meng P, He J: [Prognostic factors for survival after lung cancer surgery in elderly patients]. Zhongguo Fei Ai Za Zhi; 2007 Oct 20;10(5):391-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for survival after lung cancer surgery in elderly patients].
  • BACKGROUND: With the improvement of the surgical and anesthetic techniques, there are increasing numbers of elderly surgical patients with lung cancer.
  • METHODS: Data were retrospectively analyzed from 192 patients aged ≥70 years who underwent lung cancer surgery.
  • Tumor characteristics: squamous cell carcinoma 49.0%, adenocarcinoma 35.9%, adenosquamous carcinoma 8.3%, small cell lung cancer 4.7%, others 2.1%.
  • CONCLUSIONS: Thoracic surgery is a safe and feasible approach in elderly patients with lung cancer.
  • More limited lung surgery may be an adequate alternative in patients with associated co-morbidities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21126407.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


79. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res; 2008 Nov 15;14(22):7430-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
  • PURPOSE: In carcinomas, invasive tumor growth is accompanied by desmoplastic stroma reaction and facilitated by epithelial-mesenchymal transition (EMT) of cancer cells.
  • We investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism mesenchymal-epithelial transition (MET), and to the desmoplasia proteins collagen and elastin in non-small cell lung cancer (NSCLC).
  • RESULTS: Of the 533 patients, 48% had squamous cell carcinoma, 47% adenocarcinoma, and 5% adenosquamous carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / metabolism. Vimentin / biosynthesis
  • [MeSH-minor] Age Factors. Aged. Cell Differentiation / physiology. Collagen / biosynthesis. Elastin / biosynthesis. Epithelial Cells / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mesoderm / metabolism. Middle Aged. Prognosis. Sex Factors. Tissue Array Analysis. Versicans / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010860.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / Vimentin; 126968-45-4 / Versicans; 9007-34-5 / Collagen; 9007-58-3 / Elastin
  •  go-up   go-down


80. Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer; 2007;7:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
  • Recently, YM529 as well as other third-generation BPs have also been shown to exert anti-tumor effects against various types of cancer cells both in vitro or/and in vivo.
  • In this study, we investigate the anti-tumor effect of YM529 on non-small cell lung cancer (NSCLC).
  • METHODS: Direct anti-tumor effect of YM529 against 8 NSCLC cell lines (adenocarcinoma: H23, H1299, NCI-H1819, NCI-H2009, H44, A549, adenosquamous cell carcinoma: NCI-H125, squamous cell carcinoma: NCI-H157) were measured by MTS assay and calculated inhibition concentration 50 % (IC50) values.
  • RESULTS: We found that there was direct anti-tumor effect of YM529 on 8 NSCLC cell lines in a dose-dependent manner and their IC50 values were 2.1 to 7.9 microM and YM529 induced apoptosis and G1 arrest cell cycle with dose-dependent manner and YM529 caused down regulation of phospholyration of ERK1/2 in signaling pathways of NSCLC cell line (NCI-H1819).
  • CONCLUSION: Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one of therapeutic options for NSCLC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / pharmacology. Imidazoles / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans


81. Sugimoto Y, Semba H, Fujii S, Furukawa E, Kurano R: [Clinical analysis of primary lung cancer with a thin-walled cavity to explain the mechanism of thin-walled cavity formation]. Nihon Kokyuki Gakkai Zasshi; 2007 Jun;45(6):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary lung cancer with a thin-walled cavity to explain the mechanism of thin-walled cavity formation].
  • We report 8 rare cases of primary lung cancer which showed a thin-walled cavity on chest X-ray and CT.
  • We analyzed 8 cases (7 men, 1 woman) of primary lung cancer with thin-walled cavities admitted to our hospital between 1995 and 2006.
  • Histologically, there were 5 cases of adenocarcinoma, 2 of squamous cell carcinoma, and 1 of adenosquamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Squamous Cell / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644941.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


82. Kawano R, Hino H, Hoshino T, Yokota T, Ikeda S, Hata E: [Primary lung cancer protruding into right main bronchus, successfully treated with endoscopic neodymium yttrium aluminum garnet (Nd-YAG) laser]. Kyobu Geka; 2009 Aug;62(9):807-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lung cancer protruding into right main bronchus, successfully treated with endoscopic neodymium yttrium aluminum garnet (Nd-YAG) laser].
  • A 67-year-old male patient with a chief complaint of cough and sputum had a primary lung cancer (squamous cell carcinoma) in the upper lobe of the right lung.
  • When preoperative lung cancer patient has an obstructive pneumonia causing by the protruding tumor into the central airway, a patency treatment of bronchial airway using endoscopic Nd-YAG laser may lead to decrease a perioperative risk.
  • [MeSH-major] Bronchi / pathology. Bronchoscopy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Laser Therapy / methods. Lung Neoplasms / pathology. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670784.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA: Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer; 2006 Jan 16;94(1):128-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
  • Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival.
  • We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions.
  • High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287).
  • No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers.
  • The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P<0.0001).
  • Adenosquamous and squamous carcinomas of the lung had a lower percentage of high-level Ep-CAM expression compared to adenocarcinomas with 35.4 and 53.6%, respectively, and with 45.5 and 17.3% of tumours being Ep-CAM negative.
  • With the exception of moderately differentiated colon carcinoma, where patients not expressing Ep-CAM on their tumours showed an inferior survival (P=0.0014), correlation of Ep-CAM expression with survival did not reach statistical significance for any of the other cancer indications and subgroups.
  • This is because the most common human cancers show (i) a low frequency of Ep-CAM-negative tumours, (ii) a high frequency of Ep-CAM expression on cells of a given tumour, and (iii) for most cancers, an insignificant influence of tumour staging, grading and histology on Ep-CAM expression.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Colonic Neoplasms / genetics. Lung Neoplasms / genetics. Neoplasm Staging. Prostatic Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2001 Sep;195(1):72-9 [11568893.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):620-8 [11505407.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):883-8 [11948467.001]
  • [Cites] Cancer Gene Ther. 2002 Apr;9(4):382-9 [11960289.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):101-10 [12115595.001]
  • [Cites] Lancet. 2002 Aug 31;360(9334):671-7 [12241873.001]
  • [Cites] Cancer Immunol Immunother. 2003 Jul;52(7):429-37 [12695858.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2837-48 [12855664.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4782-91 [14581349.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2139-48 [14633587.001]
  • [Cites] Vaccine. 2004 Jan 26;22(5-6):773-80 [14741172.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1095-103 [14983507.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2659-69 [15102668.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3131-6 [15131054.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5748-58 [15195135.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5818-24 [15313925.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5391-402 [15328177.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5464-71 [15328185.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):365-75 [15349812.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Mar;76(3):1438-42 [286328.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1231-5 [7059945.001]
  • [Cites] J Biol Response Mod. 1984;3(2):138-50 [6374043.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):714-21 [2449234.001]
  • [Cites] Hybridoma. 1990 Aug;9(4):377-87 [2210778.001]
  • [Cites] Cancer Immunol Immunother. 1999 Dec;48(9):517-24 [10602889.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):701-4 [10655996.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):482-7 [10821496.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:254-61; discussion 261-2 [10911918.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • [Cites] Clin Exp Immunol. 2001 Jan;123(1):9-14 [11167991.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):550-4 [11251980.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4105-11 [11358833.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1177-83 [7909866.001]
  • [Cites] Cancer Immunol Immunother. 1997 Mar;44(1):1-9 [9111578.001]
  • [Cites] J Cell Biol. 1997 Dec 1;139(5):1337-48 [9382878.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1519-34 [9508783.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1319-23 [9563756.001]
  • [Cites] Gut. 1999 May;44(5):709-14 [10205210.001]
  • [Cites] Gene Ther. 1999 Aug;6(8):1469-74 [10467371.001]
  • [Cites] J Urol. 1999 Oct;162(4):1462-6 [10492238.001]
  • [Cites] Breast Cancer Res Treat. 2004 Aug;86(3):207-13 [15567937.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7555-65 [15569986.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):619-28 [15472903.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):83-8 [15613858.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):342-9 [15655555.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):3715-21 [15736402.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):882-7 [15756257.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2882-9 [15805290.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jun;54(6):557-70 [15570423.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1767-72 [15870832.001]
  • [Cites] Onkologie. 2005 Jun;28(6-7):347-50 [15933423.001]
  • [Cites] Mol Immunol. 2006 Mar;43(8):1129-43 [16139892.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):785-96 [16187083.001]
  • [Cites] Oncogene. 2001 Oct 11;20(46):6679-88 [11709702.001]
  • (PMID = 16404366.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human
  • [Other-IDs] NLM/ PMC2361083
  •  go-up   go-down


84. Sato T, Ito J, Shibuya H, Asano K, Watari T: Pulmonary adenosquamous carcinoma in a dog. J Vet Med A Physiol Pathol Clin Med; 2005 Dec;52(10):510-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenosquamous carcinoma in a dog.
  • A mass that developed in the lung of a 10-year-old mixed-breed dog was pathologically examined.
  • Histopathological examination showed papillary and tubular growth of glandular epithelium-like cells in some areas and growth of squamous cells arranged in nests in other areas, showing coexistence of adenocarcinoma and squamous cell carcinoma in a lung tumour.
  • Electron microscopically, the neoplastic cells of the adenocarcinoma component had features of glandular cells, with microvilli, numerous free ribosomes, large round secretory granules and intercellular desmosomes.
  • Non-keratinized squamous cells had tonofilaments and intercellular desmosomes.
  • These findings led to the diagnosis of primary adenosquamous carcinoma, which demonstrates phenotypic profiles characteristic of both epidermal keratinocytes and glandular epithelium.
  • [MeSH-major] Carcinoma, Adenosquamous / veterinary. Dog Diseases / pathology. Lung Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300659.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA: Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol; 2005 Oct;13(4):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
  • This study assessed EGFR expression in breast carcinomas with squamous differentiation.
  • The immunohistochemical (IHC) expression of EGFR was evaluated in 39 breast carcinomas with squamous differentiation (30 pure squamous, 6 adenosquamous, 3 carcinosarcomas) by use of the pharmDx assay (clone 2-18C9, DakoCytomation).
  • Cases were considered positive if at least 10% of the cells showed 1+ positivity in the squamous component.
  • Squamous differentiation was confirmed with IHC for CK5-6 (clone D5/16B4, DakoCytomation).
  • At the time of initial diagnosis, 3 patients had distant metastasis.
  • EGFR-positive tumor cells (showing squamous morphology) were also found in 1 bone, 1 lung, and 8 of 11 lymph node metastases available for evaluation.
  • All 11 lymph nodes showed squamous differentiation.
  • Nine of 280 (3%) of lymph node-positive invasive carcinomas on the tissue microarray were EGFR+; review of the initial diagnostic slides failed to reveal squamous features in all but 1 of the 9 EGFR+ tumors.
  • Breast carcinomas with squamous differentiation are a distinct subgroup of breast tumors with a very high frequency of EGFR positivity.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Squamous Cell / chemistry. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / chemistry. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Carcinoma, Adenosquamous / chemistry. Carcinoma, Adenosquamous / pathology. Carcinosarcoma / chemistry. Carcinosarcoma / pathology. Cell Differentiation. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Lung Neoplasms / chemistry. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Surg Pathol. 2006 Jul;14(3):268; author reply 269 [16959717.001]
  • (PMID = 16273187.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


86. Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, Yamashita Y: Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol; 2008 Apr;3(4):358-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FDG uptake of each lesion was quantitatively measured by a contrast ratio of standard uptake value (SUV-CR) between the lesions and contralateral lung.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379353.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


87. Mazza E, Maddau C, Ricciardi A, Falchini M, Matucci M, Ciarpallini T: On-site evaluation of percutaneous CT-guided fine needle aspiration of pulmonary lesions. A study of 321 cases. Radiol Med; 2005 Sep;110(3):141-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Three hundred and twenty-one FNAs of lung lesions were performed in 312 patients (218 males, 94 females; age range: 20-86 years; mean age: 66 yrs).
  • Smears were prepared in the Radiology Department and stained using a quick method by a cytopathologist: the sample adequacy was assessed and, if possible, a preliminary diagnosis was made.
  • CONCLUSIONS: CT guided aspiration cytology can be a safe and fast procedure for lung nodule characterisation.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Lung / pathology. Lung Neoplasms / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pneumothorax / radiography. Radiography, Thoracic

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200036.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


88. Yin R, Xu L, Ren B, Jiang F, Fan X, Zhang Z, Li M, Hu Z: Clinical experience of lobectomy with pulmonary artery reconstruction for central non-small-cell lung cancer. Clin Lung Cancer; 2010 Mar 1;11(2):120-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience of lobectomy with pulmonary artery reconstruction for central non-small-cell lung cancer.
  • BACKGROUND: In patients with central lung cancer, lobectomy can be achieved without pneumonectomy by surgical reconstruction of the pulmonary artery (PA).
  • CONCLUSION: In our department, PA reconstruction has been more frequently and actively performed for patients with central lung cancer, especially for some patients with a lower lobe tumor.
  • Although the morbidity and mortality is acceptable, surgeons should be more attentive to lethal postoperative complications such as ARDS induced by lung ischemia-reperfusion injury.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Adenosquamous / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy. Pulmonary Artery / surgery


89. Meng YH, Li S, Hu T, Ma D, Lu YP, Wang H: [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma]. Chin J Cancer; 2010 Jan;29(1):15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma].
  • BACKGROUND AND OBJECTIVE: The incidence of cervical adenosquamous carcinoma is relatively low.
  • This study was to analyze the clinicopathologic characteristics and prognostic factors of cervical adenosquamous carcinoma.
  • METHODS: Clinical data of 44 cervical adenosquamous carcinoma patients and 88 cervical adenocarcinoma patients(control), treated from January 2002 to December 2007, were analyzed using Chi-square test, Kaplan-Meier method, log-rank test, and Cox regression model.
  • RESULTS: The proportion of large tumors (maximal diameter > 4 cm) was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (47.7% vs. 28.4%, P<0.05); the proportion of poorly differentiated tumors was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (56.8% vs. 30.7%, P<0.05).
  • CONCLUSIONS: Cervical adenosquamous carcinoma is characterized by large tumor size and poor differentiation.
  • There is no difference in prognosis between cervical adenosquamous carcinoma and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Kaplan-Meier Estimate. Lung Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Pelvic Neoplasms / secondary. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden


90. Tsukioka T, Nishiyama N, Iwata T, Izumi N, Mizuguchi S, Morita R, Inoue K, Suehiro S: Early recurrence of completely resected N2-positive non-small-cell lung cancer. Gen Thorac Cardiovasc Surg; 2007 Mar;55(3):113-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrence of completely resected N2-positive non-small-cell lung cancer.
  • It is suggested that the number of N1 stations with metastasis is a risk factor for early recurrence and a poor prognostic factor in N2 disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Neoplasm Recurrence, Local. Pneumonectomy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2692-9 [10561343.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):167-73 [14739037.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Nov;22(5):695-700 [12414032.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Mar;25(3):434-8 [15019674.001]
  • [Cites] Ann Thorac Surg. 2005 May;79(5):1682-5 [15854954.001]
  • [Cites] Lung Cancer. 2002 May;36(2):115-24 [11955645.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2981-9 [10944131.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Jul;108(1):158-61 [8028360.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Dec;76(6):832-9 [713589.001]
  • [Cites] Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23 [15337041.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1135-40 [10838529.001]
  • [Cites] Ann Thorac Surg. 2000 Oct;70(4):1154-9; discussion 1159-60 [11081861.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Jul;51(7):297-301 [12892460.001]
  • [Cites] J Thorac Cardiovasc Surg. 1989 Apr;97(4):623-32 [2927166.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4384s-4391s [16857815.001]
  • (PMID = 17447509.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J: Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res; 2009 May 1;69(9):3937-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
  • Using a high-throughput cancer cell line screening platform, we found that only 2 of 637 tested human tumor-derived cell lines show significant sensitivity to single-agent sunitinib exposure.
  • These two cell lines [a non-small-cell lung cancer (NSCLC) and a rhabdomyosarcoma] showed expression of highly phosphorylated PDGFRA.
  • In the sunitinib-sensitive adenosquamous NSCLC cell line, PDGFRA expression was associated with focal PFGRA gene amplification, which was similarly detected in a small fraction of squamous cell NSCLC primary tumor specimens.
  • Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected, and silencing PDGFRA or PDGFC expression by RNA interference inhibited proliferation.
  • A similar codependency on PDGFRA and PDGFC was observed in the sunitinib-sensitive rhabdomyosarcoma cell line.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 May 15;112(10):2119-29 [18338812.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3389-95 [18451166.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2442-9 [18458038.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):632-7 [10874667.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]
  • [Cites] Oncogene. 2001 Feb 1;20(5):626-33 [11313995.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cell. 1984 Nov;39(1):89-97 [6091919.001]
  • [Cites] Cell. 1986 Jul 18;46(2):155-69 [3013421.001]
  • [Cites] Cell. 1993 Apr 23;73(2):321-34 [7682895.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5357-64 [15928335.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21 [16461907.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):524-8 [17049587.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):254-8 [17262795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 [18077425.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):184-93 [17950782.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):650-6 [18235126.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • (PMID = 19366796.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / P50 CA090578-060008; United States / NCI NIH HHS / CA / CA115830-04; United States / NCI NIH HHS / CA / P20 CA090578-06; United States / NCI NIH HHS / CA / R01 CA115830-04; United States / NCI NIH HHS / CA / CA090578-060008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Indoles; 0 / Ligands; 0 / Lymphokines; 0 / Platelet-Derived Growth Factor; 0 / Pyrroles; 0 / RNA, Small Interfering; 0 / platelet-derived growth factor C; 0 / sunitinib; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ NIHMS98241; NLM/ PMC2676215
  •  go-up   go-down


92. Dong QG, Han BH, Huang JS, Yang LM, Huang J, Zhao CY, Lu LQ: [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):686-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].
  • OBJECTIVE: To analyze the incidence and profile of mutations in epidermal growth factor receptor (EGFR) in Chinese patients with non-small cell lung cancer (NSCLC).
  • METHODS: A total of 176 cases of NSCLC tissue was enrolled in this study, among which 123 normal lung samples were also included.
  • RESULTS: The EGFR gene in exon 19-21 was of wild type in all normal lung tissues detected.
  • Mutations were found in 57 cases of 176 lung cancer samples, with an incidence of 32. 4%.
  • The EGFR mutations were more frequent in female patients than male ones, in adenocarcinoma and adenosquamous cell carcinoma versus cancer of other histologies.
  • These mutations are more frequently detected in female, adenocarcinoma and adenosquamous cell carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Aged. Amino Acid Sequence. Base Sequence. Carcinoma, Squamous Cell / genetics. Codon. DNA Mutational Analysis. Exons. Female. Gene Deletion. Humans. Male. Middle Aged. Mutation, Missense. Sex Factors


93. Satoh Y, Hoshi R, Ishikawa Y, Horai T, Okumura S, Nakagawa K: Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology. Ann Thorac Surg; 2007 Jan;83(1):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology.
  • BACKGROUND: Cytologic approaches such as pleural lavage cytology (PLC) are considered as possible aids to assessing prognosis of lung cancers.
  • However, there is some controversy whether radical surgery is warranted based on the positive PLC findings with stage I non-small cell lung cancers (NSCLCs).
  • METHODS: From January 1991 to December 2002, PLC was performed before any manipulation or resection of the lung for 853 consecutive patients who had no macroscopic pleural effusion, dissemination, or diffuse adhesions and who subsequently underwent curative resection for NSCLCs.
  • RESULTS: PLC findings were positive in 41 patients (4.8%), rates being most frequent with adenosquamous carcinomas and adenocarcinomas.
  • CONCLUSIONS: PLC is a distinct prognostic factor for early stage lung carcinomas.
  • Thus, we suggest that cytologic examination of PLC should be routine, even for patients with stage I NSCLCs before beginning lung resection.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Pleura / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2007 Jan;83(1):202-3 [17184662.001]
  • (PMID = 17184661.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


94. Rea F, Marulli G, Schiavon M, Zuin A, Hamad AM, Rizzardi G, Perissinotto E, Sartori F: A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg; 2008 Sep;34(3):488-92; discussion 492
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer.
  • OBJECTIVE: Sleeve lobectomy represents an effective and widely accepted surgical therapy for non-small cell lung carcinoma (NSCLC).
  • Pathology revealed 167 (83.9%) squamous carcinomas, 23 (11.6%) adenocarcinomas, 7 (3.5%) large cell and 2 (1%) adenosquamous carcinomas.
  • This emphasises the importance of a learning curve and encourages the performance of this procedure in experienced centres.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pulmonary Artery / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579399.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, Takamochi K, Suzuki K, Yamada T, Niwa H, Ohashi R, Ogawa H, Mori H, Kitamura H, Kaneko T, Tsuneyoshi T, Sugimura H: PIK3CA mutation and amplification in human lung cancer. Pathol Int; 2007 Oct;57(10):664-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA mutation and amplification in human lung cancer.
  • To explore the significance of phosphatidylinositol-3-kinase, catalytic, alpha (PIK3CA) in the carcinogenesis in human lung, mutations and copy number changes were investigated in 148 Japanese patients with primary cancer of the lung.
  • For biological validation, the effects of exogenously expressed wild-type and mutated PIK3CA were studied in an immortalized human airway epithelial cell line.
  • The prevalence of copy number gains was higher in men, smokers, and in patients with squamous cell carcinoma than in the opposite categories.
  • The present demonstrates an important role of PIK3CA in human lung carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma / genetics. Lung Neoplasms / genetics. Mutation. Phosphatidylinositol 3-Kinases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Line, Transformed. DNA, Neoplasm / analysis. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Int. 2007 Nov;57(11):757
  • (PMID = 17803655.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


96. Manxhuka-Kerliu S, Telaku S, Ahmetaj H, Baruti A, Loxha S, Kerliu A: Colorectal cancer: prognostic values. Bosn J Basic Med Sci; 2009 Feb;9(1):19-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer: prognostic values.
  • After lung cancer colorectal cancer (Cc) is ranked the second, as a cause of cancer-related death.
  • There were investigated 149 cases of resection specimen with colorectal cancer, which were fixed in buffered neutral formalin and embedded in paraffin.
  • Adenocarcinoma was the most frequent histological type found in 85,90% of cases, in 60,94% of males and 39,06% of females; squamous cell carcinoma in 7,38%, in 63,63% of males and 36,36% of females; mucinous carcinoma in 4,68%, in 57,15% of males and 42,85% of females; while adenosquamous carcinoma, undifferentiated carcinoma and carcinoma in situ in 0,71% of cases each.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colorectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Colon / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Rectum / pathology. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):385-8 [10379860.001]
  • [Cites] Surg Laparosc Endosc. 1998 Aug;8(4):269-72 [9703598.001]
  • [Cites] Am Fam Physician. 2000 Mar 15;61(6):1759-70, 1773-4 [10750881.001]
  • [Cites] Nutr Cancer. 1999;33(1):95-9 [10227050.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):376-88 [12692203.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):832-9 [15492565.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Br J Surg. 1992 Jul;79(7):608-13 [1643467.001]
  • [Cites] Surg Today. 1996;26(9):760-1 [8883258.001]
  • [Cites] Stat Bull Metrop Insur Co. 1999 Jul-Sep;80(3):23-32 [10418079.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):140-2 [17133267.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):673-8 [9708930.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1128-41 [16802325.001]
  • [Cites] Hum Pathol. 1983 Nov;14 (11):931-68 [6629368.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):180-90 [18460593.001]
  • [Cites] World J Gastroenterol. 2007 Jun 7;13(21):3009-15 [17589956.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):857-65 [18667357.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):698-702 [4041728.001]
  • [Cites] Pathology. 1993 Jul;25(3):219-22 [8265235.001]
  • (PMID = 19284390.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


97. Diaz A, Batista AE, Montero E: Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. J Interferon Cytokine Res; 2009 Aug;29(8):433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor.
  • Interferon-alpha (IFN-alpha) induces growth inhibition but also may up-regulate the EGFR expression in some cancer cell lines.
  • We aimed to determine whether the IFN-alpha combined with an EGFR-specific monoclonal antibody (nimotuzumab) may affect the growth of human tumor epithelial cell lines with different EGFR expression levels.
  • H125, a lung adenosquamous carcinoma, and A431, a vulvar epidermoid carcinoma, cell lines express intermediate and high levels of EGFR, respectively, whereas MDA MB231, a breast adenocarcinoma cell line expresses undetectable levels of EGFR measured by flow cytometry/FACS.
  • We found that IFN-alpha alone inhibited in a dose-dependent fashion the growth of all cell lines, but only up-regulated the EGFR expression in the lung carcinoma-derived cell line.
  • Noteworthy, the combined treatment did not modify the complement-mediated cytotoxicity of the antibody although the antiproliferative activity of nimotuzumab in H125 cells in vitro increased when an IFN-alpha-conditioning treatment was used.
  • In conclusion, this study may provide insights about the rational use of EGFR inhibitors into the immunopharmacological management of targeted therapies including the IFN-alpha for lung cancer.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Epithelial Cells / immunology. Growth Inhibitors / metabolism. Immunologic Factors / pharmacology. Immunotherapy. Interferon-alpha / metabolism. Lung Neoplasms / immunology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Cell Growth Processes / drug effects. Cell Line, Tumor. Cell Separation. Complement System Proteins / metabolism. Cytotoxicity, Immunologic / drug effects. Dose-Response Relationship, Immunologic. Drug Synergism. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Vulvar Neoplasms / immunology. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / pathology. Vulvar Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514842.001).
  • [ISSN] 1557-7465
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Growth Inhibitors; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / nimotuzumab; 9007-36-7 / Complement System Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


98. Spaggiari L, D' Aiuto M, Veronesi G, Pelosi G, de Pas T, Catalano G, de Braud F: Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg; 2005 Jan;79(1):234-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer.
  • BACKGROUND: Extended pneumonectomy with partial resection of the left atrium for lung cancer is not frequently performed; therefore, its results remain controversial.
  • METHODS: From November 1996 to December 2003, 15 patients underwent extended pneumonectomy with partial resection of the left atrium for lung cancer, without cardiopulmonary bypass.
  • The T status was T4 in 10 patients, pT3 in 3 patients, and T0 in the remaining 2 patients.
  • The were 10 squamous cell carcinomas (60%), 2 adenocarcinomas, 1 adenosquamous carcinoma, 1 mucoepidermoid carcinoma, and 1 atypical carcinoid tumor.
  • CONCLUSIONS: Extended pneumonectomy with partial resection of the left atrium for advanced lung cancer is a feasible procedure, with low postoperative morbidity and mortality.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Heart Atria / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Antineoplastic Agents / therapeutic use. Arrhythmias, Cardiac / epidemiology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Cardiopulmonary Bypass. Combined Modality Therapy. Databases, Factual. Female. Humans. Length of Stay / statistics & numerical data. Life Tables. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620949.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 11
  •  go-up   go-down


99. Kadokura M, Kamio Y, Kitami A, Nakajima H, Kushihashi T, Shiokawa A, Nonaka M: [Completion pneumonectomy 9 years after middle lobectomy for adenocarcinoma]. Kyobu Geka; 2005 May;58(5):361-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Completion pneumonectomy 9 years after middle lobectomy for adenocarcinoma].
  • We report herein a case of CP for a patient with recurrent lung cancer.
  • A 63-year-old man was admitted to our hospital for evaluation of abnormal shadows in the right lung field in October 2002.
  • Bronchofiberscopic cytology revealed squamous cell carcinoma.
  • Right completion pneumonectomy was performed on suspicion of metachronous multiple lung cancers 4 days later.
  • Histopathologically, resected specimens represented adenosquamous carcinoma similar to the prior lesion from the middle lobe, and examination revealed that the tumor represented a recurrence following middle lobectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881232.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Maley SN, Schwartz SM, Johnson LG, Malkki M, Du Q, Daling JR, Li SS, Zhao LP, Petersdorf EW, Madeleine MM: Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. Int J Immunogenet; 2009 Dec;36(6):367-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.
  • We conducted a population-based case-control study to test the hypothesis that common genetic variation in CXCL12 individual single nucleotide polymorphism (SNP) alleles and haplotypes] is associated with the risk of cervical carcinoma.
  • Cases (n = 917) were residents of western Washington State diagnosed with invasive squamous cell cervical carcinoma (SCC), invasive adenocarcinoma or adenosquamous carcinoma, or adenocarcinoma in situ of the cervix.
  • The minor allele of intronic SNP rs266085 was inversely associated with cervical cancer under a recessive genetic effects model (OR = 0.74, 95% CI: 0.56-0.98).
  • A stepwise procedure identified rs17885289, rs266085 and 3'-untranslated region (UTR) SNP rs266093 as the most parsimonious subset of SNPs necessary to define the haplotype inversely associated with cervical cancer risk in our study.
  • A 3'-UTR SNP, rs1801157, previously found to be related to HIV pathogenesis, was not associated with cervical cancer risk.
  • Further population-based studies are warranted to confirm these associations between genetic variation in CXCL12 and cervical cancer risk.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Tissue Antigens. 2006 Feb;67(2):127-33 [16441483.001]
  • [Cites] Int J Mol Med. 2006 Oct;18(4):785-93 [16964435.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):478-83 [17362322.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):577-86 [17366619.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5056-62 [17785557.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] Oncol Rep. 2007 Dec;18(6):1583-7 [17982648.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3532-9 [18451182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1790-9 [18628433.001]
  • [Cites] BMC Genet. 2008;9:90 [19102730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21 [10613347.001]
  • [Cites] Eur J Neurosci. 2000 Jun;12(6):1857-66 [10886327.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2597-606 [12239174.001]
  • [Cites] Am J Epidemiol. 2003 Feb 1;157(3):218-26 [12543621.001]
  • [Cites] Nat Genet. 2003 May;34(1):70-4 [12692554.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] Biostatistics. 2003 Oct;4(4):513-22 [14557108.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] J Med Genet. 2004 May;41(5):e59 [15121787.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):233-45 [15339043.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):829-33 [8752280.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8 [8827359.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1101-9 [9064327.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):381-6 [9833747.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Immunol Rev. 2005 Feb;203:235-43 [15661033.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] J Infect Dis. 2005 Mar 15;191(6):969-76 [15717274.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] J Mol Biol. 2005 Apr 22;348(1):43-62 [15808852.001]
  • [Cites] Hum Mol Genet. 2005 Jun 15;14(12):1579-85 [15843397.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):261-6 [15978329.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):311-5 [15955592.001]
  • [Cites] Tissue Antigens. 2005 Oct;66(4):321-4 [16185329.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):276-9 [16249700.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):521-6 [16284526.001]
  • [Cites] Genes Immun. 2005 Dec;6(8):691-8 [16177829.001]
  • [Cites] Gene. 2006 Jun 7;374:174-9 [16626895.001]
  • (PMID = 19788587.001).
  • [ISSN] 1744-313X
  • [Journal-full-title] International journal of immunogenetics
  • [ISO-abbreviation] Int. J. Immunogenet.
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / T32HG00035; United States / NCI NIH HHS / CA / CA112512-02; United States / NCI NIH HHS / CA / R01CA112512; United States / NCI NIH HHS / CA / R01 CA112512-02; United States / NCI NIH HHS / CA / P01 CA042792-219003; United States / NCI NIH HHS / CA / P01CA04279; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / CA112512-01; United States / NIEHS NIH HHS / ES / P30ES07033; United States / NHGRI NIH HHS / HG / T32 HG000035; United States / NCI NIH HHS / CA / CA112512-04; United States / NCI NIH HHS / CA / R01 CA112512-01; United States / NCI NIH HHS / CA / R01 CA112512-03; United States / NIEHS NIH HHS / ES / P30 ES007033; United States / NCI NIH HHS / CA / R01 CA112512-04; United States / NCI NIH HHS / CA / R25CA094880; United States / NCI NIH HHS / PC / N01-PC-35412; United States / NCI NIH HHS / CA / CA042792-219003; United States / NCI NIH HHS / CA / P01 CA042792; United States / NCI NIH HHS / CA / CA112512-03; United States / NCI NIH HHS / CA / CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12
  • [Other-IDs] NLM/ NIHMS144226; NLM/ PMC2784202
  •  go-up   go-down






Advertisement